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Neisseria gonorrhoeae, a Gram negative bacterium, causes the sexually transmitted infection, 
gonorrhoea. This organism is known to rapidly develop resistance and has over the years 
evolved into a highly drug resistant species. Treatment options for gonorrhoea are now limited 
as N.gonorrhoeae has developed resistance to previously and currently recommended 
antimicrobial drugs.  Effective treatment has become a challenge in many parts of the world 
including KwaZulu-Natal, South Africa. Resistance to third generation cephalosporins that are 
one of the remaining options for monotherapy are being reported globally. In this study, an 
evaluation of susceptibility of previously (ciprofloxacin, ofloxacin, penicillin and tetracycline) 
and currently (azithromycin, cefixime and ceftriaxone) used antimicrobials to currently 
circulating strains of N.gonorrhoeae was undertaken. MICs were determined using the agar 
dilution with multipoint inoculation method. Further, characterization of resistance 
mechanisms amongst tetracycline resistant isolates was done by PCR and gel electrophoresis. 
The tetM gene is known to confer high level tetracycline resistance and there are 2 known 
variants of this gene which are the American and Dutch respectively. 
A total of 1220 patients were recruited from male and female patients presenting to 2 clinics: 
Boom Street Clinic in Pietermaritzburg, Umgundundlovu and Umlazi Section D Clinic in 
Umlazi, eThekwini. Three hundred and nineteen isolates of N.gonorrhoeae was obtained from 
both clinics. The results from this study have shown that despite the previously used 
antimicrobials not being in the current treatment management of sexually transmitted infections 
(STIs), N.gonorrhoeae isolates remain resistant. All isolates (100%) showed high level 
tetracycline resistance with MIC values ranging from 16 mg/L to ≥32mg/L. Ninety eight (98 
%) percent of isolates displayed MIC values in the intermediate and resistant range for 




Two isolates were resistant to cefixime, but not to ceftriaxone. The American and Dutch 
variants of the tetM gene was found in 264 and 29 isolates respectively. Twenty six isolates did 
not harbour any tetM gene. This suggests alternative mechanisms of resistance and requires 




CHAPTER 1: INTRODUCTION 
1.1 Background 
Gonorrhoea, a sexually transmitted infection (STI) has become a significant public health 
concern amid growing antimicrobial resistance (Unemo & Shafer 2015). Neisseria 
gonorrhoeae, the aetiologic agent of the infection has been referenced in biblical times, making 
it one of the oldest diseases to have plagued mankind (Edwards & Apicella 2004). 
N.gonorrhoeae, was first identified by Albert Neisser in 1879 and cultured in the laboratory in 
1882 (Edwards & Apicella 2004; Lewis 2007a). Sulfonamide was the first antimicrobial agent 
used to treat the disease in 1936, followed by penicillin in 1943 which resulted in a decrease in 
the prevalence of N.gonorrhoeae infections globally (Unemo & Shafer 2014; Edwards & 
Apicella 2004). 
The dawn of the 21st century was met with global increase in the prevalence of N.gonorrhoeae 
infection. This was due the emergence of drug resistant strains of the organism. Recent 
literature has reported N.gonorrhoeae strains with documented resistance to almost all classes 
of antimicrobials including sulfonamides, cephalosporins, tetracyclines, penicillins, macrolides 
and fluoroquinolones (Unemo & Shafer 2015). Resistance is mediated via numerous 
mechanisms including drug inactivation, alteration of the drug target, expulsion of the drug via 
efflux mechanisms and changes in permeability of the bacterial cell (Patel et al. 2011). 
Antimicrobial resistance is a major concern in South Africa (SA). The first penicillinase 
producing N.gonorrhoeae (PPNG) was reported in Durban and Johannesburg in 1977 (Robins-
Browne et al. 1977; Hallett et al. 1977). Further concerns regarding resistance to gonorrhoea 




reported that 60% of patients attending the Prince Cyril Zulu Centre for Communicable 
Diseases in Durban, which houses one of the largest STI clinics in the province.  and 29% of 
patients attending a Johannesburg clinic that was monitoring urethral culture from men with 
MUS attending Esselen Street Clinic in central Johannesburg and Alexandra Health Centre 
which are primary health care facilities displayed resistance to ciprofloxacin (Moodley & 
Sturm 2005; Lewis 2007.; Kahn 2006). One of the factors driving antimicrobial drug resistance 
is the inappropriate utilization of antibiotics. Surveillance systems to monitor drug 
susceptibility of the organism responsible do not feature on the national STI control program 
in South Africa. Screening of drug resistance occurs only in research settings (Moodley & 
Sturm 2005). 
Mismanagement of N.gonorrhoeae infection can lead to severe complications including pelvic 
inflammatory disease, infertility, neonatal conjunctivitis and blindness, male infertility and 
disseminated gonococcal infections (Edwards & Apicella 2004). The interaction of gonorrhoea 
infections with the human immunodeficiency virus (HIV) epidemic is a further concern in 
South Africa. The inflammatory response and compromised mucosal integrity associated with 
N.gonorrhoeae infection has been reported to increase acquisition of HIV subtype 1 (Edwards 
& Apicella 2004).  
Treatment of resistant strains of N.gonorrhoeae is currently limited to the extended spectrum 
cephalosporins (ESCs) viz: cefixime and ceftriaxone (Unemo & Shafer 2014). These drugs 
form the first line empirical regime in most countries. However, susceptibility to these agents 
have decreased globally (Cámara et al. 2012; Ohnishi et al. 2011; Unemo et al. 2012). 
Recently, multi-drug therapy has been advocated in an effort to delay the emergence of 




may not be sufficient to alleviate the emergence of resistance and spread of drug resistance 
(Unemo & Shafer 2014).  
1.2 Epidemiology 
Gonorrhoea ranks as the most common bacterial STI in the world. In its 2008 global STI report, 
the World Health Organization (WHO) estimated that more than 498 million incident cases of 
STI’s are diagnosed annually (WHO 2012). Of these cases, 106 million cases were attributed 
to N. gonorrhoeae infection. A substantial increase in the number of cases of gonorrhoea 
infections were reported from 2005 to 2008 with 87 million cases in 2005 to 106 million cases 
in 2008. An overall increase of 21% in the global incidence of N.gonorrhoeae infections were 
reported (WHO 2012). The reported prevalence of N. gonorrhoeae infections was 36 million 
adult infections at any point during 2008. The WHO estimate of incident STI cases for the 
African Region was 93 million. Of these cases, 21 million were attributed to N. gonorrhoeae 
infections. Accurate reporting systems for STI infections outside Western Europe and North 
America are lacking. This includes South Africa, were the incidence of STIs including N. 
gonorrhoeae infections is unknown. The data on STI’s in South Africa are sourced from 
surveys of women attending antenatal and family planning clinics (Lewis & Marumo 2009). 
The incidence of N.gonorrhoeae in the African region in 2008 was 18.5 and 27.6 per 1000 in 
females and males respectively (WHO 2012). The incidence rate of STIs among young women 
in KZN, SA was reported to be 20/100 women-years while the prevalence of STIs was 13% 
(Naidoo & Wand 2014). Other studies in SA have also reported similar STI incidence rates 
(Kapiga et al. 2009; Mlisana et al. 2012; Feldblum et al. 2010).  Within South Africa, 
N.gonorrhoeae is known to cause 70-80% of male urethritis syndrome and accounts for 




1.3 Physical Characteristics, transmission and clinical manifestations of Neisseria 
gonorrhoeae 
N.gonorrhoeae is a Gram-negative diplococcus that has the ability to colonise and invade the 
mucosal surfaces of the endocervix, urethra, anus, conjunctiva and pharynx. N.gonorrhoeae 
belongs to the order Neisseriales, family Neisseriaceae and genus Neisseria. Gonococci are 
non-sporulating and non-flagellated bacteria. N.gonorrhoeae has components such as outer 
membrane proteins, lipopolysaccharides and pili that assist in the binding and attachment of 
bacteria to epithelial cells which makes it a very successful pathogen (Tapsall 2001). 
N.gonorrhoeae is able to undergo genetic variation whereby the microbe is able to incorporate 
new genetic material by either transformation or conjugation (Patel et al. 2011). This process 
has allowed N.gonorrhoeae to acquire penicillinase producing plasmids (Patel et al. 2011). 
Neisseria gonorrhoeae has also been able to acquire genetic material from related organisms 
and this is antigenic variability (Patel et al. 2011).  
There are two species in the genus Neisseria that are known to be pathogenic to humans 
namely; N.gonorrhoeae and N.meningitidis. There are roughly 30 nonpathogenic species 
which include; N.lactamica, N.sicca, N.cinerea, N.flavescens, N.subflava, and N.mucosa 
commonly found in the nasopharynx of young children and upper respiratory tract which may 
exist as part of the normal flora (Barth et al. 2009). 
Close sexual contact with an individual harboring the bacteria is the primary mode of 
transmission of the disease (Patel et al. 2011). Transmission from mother to child during 
childbirth is also a mode of transmitting the disease. Women are disproportionately affected by 
the disease. The disease is more effectively transmitted from men to women with a probability 
of 50-70%  compared to transmission from women to men which records a probability of 20-




male and female genitalia as well as the duration of contact of the bacteria with the target 
membranes after exposure (Edwards & Apicella 2004).  
Clinical presentation of the disease is affected by the nature of the infecting strain and the site 
of infection. Most gonococcal infections in women result in asymptomatic infection or mild 
symptoms. These include mild irritation and discharge. These symptoms may only become 
significant once infection spreads to the upper genital tract.  In men, the symptoms of urethritis 
and discharge are more evident than in women. The disease has been reported to disseminate 
leading to chronic joint infection and sepsis. Clinical manifestation in neonates include 
conjunctivitis, blindness, sepsis and joint infection (Edwards & Apicella 2004). 
1.4 Diagnosis of N.gonorrhoeae  
The diagnosis of N.gonorrhoeae is established by the visualization of the organism on light 
microscopy, culture or nucleic acid amplification tests (NAATs). N.gonorrhoeae can be 
detected by Gram- and methylene blue staining techniques utilizing light microscopy (Unemo 
et al 2013).  Microscopy is not recommended as the only method for diagnosis due to its low 
sensitivity, especially in female patients. To date, culture remains as the gold standard for the 
diagnosis of N.gonorrhoeae. This method has high sensitivity and specificity compared to 
microscopy and remains the only established method for antimicrobial susceptibility testing 
(Unemo et al 2013). However the sensitivity and specificity of these tests are highly dependent 
on the specimen. For symptomatic patient specimens, microscopy is highly specific and 
sensitive however in asymptomatic patient specimens, microscopy sometimes fails to detect 
the presence of the organism. In resourced settings, NAATs are rapidly replacing culture 
techniques. This method has a higher sensitivity than the preceding diagnostic techniques; 




A disadvantage of NAATs is that isolates for susceptibility testing are not available. The 
sensitivity of detection for pharyngeal and rectal specimens is greatly increased NAAT testing. 
Cervical, vaginal and urethral swabs can be used for GC NAAT testing, not only urine.  
1.5 Antimicrobial Susceptibility Testing 
The global dissemination of antimicrobial resistant strains of N.gonorrhoeae highlights the 
urgent need for periodic surveillance and antimicrobial susceptibility testing. The disk 
diffusion method differentiates between drug resistant and drug susceptible strains but does not 
determine the actual MIC of the infecting strain. This technique utilizes discs containing known 
antimicrobial concentrations. Growth around the discs determines the level of resistance of the 
organism. The minimum inhibitory concentration (MIC) for the various antimicrobials used to 
treat N.gonorrhoeae infection is obtained using the agar dilution, or E-test® methods. The agar 
dilution method is the gold standard for MIC determination of N.gonorrhoeae. The test is done 
on Gonococcus (GC) media supplemented with yeast autolysate and horse blood. The E-test® 
method of MIC determination makes use of an encoded plastic strip the with the antimicrobial 
drug concentration on a decreasing gradient. (Unemo et al 2013). Incubation of the strip with 
the bacterial isolate produces an ellipse. The MIC is recorded at the point of intersection of the 
ellipse and the gradient scale marked on the strip. (Unemo et al 2013). 
1.6 Treatment of N.gonorrhoeae 
Sexually Transmitted Diseases (STDs) in South Africa are managed syndromically in the 
public sector. In the private sector, often an attempt at laboratory diagnosis is made.  The aim 
of syndromic management is to ensure that patients presenting with signs and symptoms are 
treated at the first point of contact with high quality care. This eliminates the delays of 




the STDs (Unemo et al 2013). The approach of syndromic management of symptomatic STIs 
has been practiced in South Africa for close to 20 years. Some of the antibiotics that are listed 
in sections 1.6.1 are still used for mono- or dual therapy in remote communities such as Western 
Australia where the prevalence is not high (Lahra et al 2016). 
1.6.1 Previously used Antimicrobials to treat infection with N.gonorrhoeae 
 
1.6.1.1 Sulfonamides 
Sulfonamides were the earliest class of antimicrobials used to treat gonorrhoea infections 
(Dillon et al. 2015). Sulfanilamide was discovered by Gerhard Gomagk in 1935 (Oriel 1994; 
Lewis 2010). The first studies that made use of sulphanilamide for the treatment of gonococci 
were in 1937 in USA, UK and Germany (Kampmeier 1983).  In 1940-41, sulfapyridine became 
available for treatment. Resistance to sulphonamides emerged in 1944 and resulted in treatment 
failure in over 30% of patients (Kampmeier 1983). By the end of that decade widespread 
resistance in vitro was documented in approximately 90% of gonococcal isolates (Lewis 2007). 
1.6.1.2 Penicillin  
 
 Penicillin was the drug of choice for gonorrhoea treatment following its introduction in 1944 
(Patel et al. 2011). Penicillin was discovered by Alexander Fleming in 1929 (Fleming 1980) 
and was known as the “wonder drug” as it was used to treat numerous infectious diseases 
(Sternberg & Turner 1944; Mahoney et al. 1943). Penicillin remained the treatment option for 
gonorrhoea for decades with increasing drug dosages being applied to treat the infection until 
resistance to the drug was documented. (Patel et al. 2011). Penicillin was first used to treat 
urethritis in 1943 (Dillon et al. 2015). Treatment failure was reported in the early 1950s, 




 1976 and the  emergence of two types of β-lactamase encoding plasmids (Ashford et al. 1975). 
These plasmids originated in Southeast Asia and sub-Saharan West Africa and result in high-
level penicillin resistance (Ashford et al. 1975; Percival et al. 1976; Phillips 1976). Penicillin 
was discontinued as the first line antimicrobial drug in many parts of the world following the 
emergence of chromosomally mediated resistant gonorrhoea (Unemo & Shafer 2014). This 
resulted in worldwide discontinuation of penicillin for gonorrhoea treatment by 1985 (Dillon 
et al. 2015). 
1.6.1.3 Tetracycline  
 
Tetracycline was discovered in 1945 by Benjamin Minge Duggar (Zakeri & Wright 2008). 
Tetracycline became the alternate treatment option amid increasing penicillin resistance. (Patel 
et al. 2011). It is also utilized in patients that are allergic to penicillin (Reyn et al. 1958). The 
use of this drug is not recommended as several doses are required over an extended period. 
This brings into play the issue of compliance and exerts selective pressure on N.gonorrhoeae 
leading to the development of chromosomally mediated resistance to tetracycline (Dangor et 
al. 2010; Dillon et al. 2015). The drug is not administered to pregnant women and small 
children as it is associated with  discolouration of the teeth in children and suppression of 
skeletal growth in premature infants (Speer et al. 1992). Tetracycline was one of the most 
extensively used antimicrobials during the 1950s and 1960s in the United States as it was 
relatively cheap, had few side effects and displayed broad spectrum activity (Speer et al. 1992).  
In 1985, reports of plasmid mediated resistance to tetracycline emerged in the United States of 
America (USA) (Roberts et al. 1988). This was the first report of the tetM plasmid and was 
designated the American tetM plasmid (Morse et al. 1986). The Dutch variant of the tetM 




the treatment guidelines in the USA following the emergence of the tetM determinant that was 
responsible for high-level tetracycline resistance (Morse et al. 1986). In South Africa, high-
level tetracycline resistance was first reported in Bloemfontein(Chalkley et al. 1997). 
1.6.1.4 Spectinomycin  
 
Spectinomycin, discovered in 1961,  was recommended for the management of N.gonorrhoeae 
infections following the emergence of penicillinase producing N.gonorrhoeae cases (Lewis 
and Lukehart 2011). Reports of resistance to spectinomycin emerged from the Netherlands in 
1967 (Stolz et al. 1975), Philippines in 1981 (Ashford et al. 1981) and London, United 
Kingdom in 1983 (Ison et al. 1983) . This led to the worldwide discontinuation of the drug as 
first-line monotherapy treatment for gonorrhoea (Unemo & Shafer 2014). A recent study in the 
province of Eastern Cape of South Africa showed that spectinomycin is an effective treatment 
option for patients with gonococcal infections (Faye et al. 2015). However in South Africa, 




In the 1960s synthetic quinolone antimicrobials were discovered by George Lesher and 
coworkers (Lesher et al. 1962). Fluoroquinolones used to treat gonorrhoea included 
ciprofloxacin and ofloxacin. From mid to late 1980s ciprofloxacin was widely used to treat 
gonococcal infections. Reports of clinical failures emerged in the  1990s (Gransden et al. 1990; 
Unemo & Shafer 2014). Resistance to ciprofloxacin has been noted in the Far East, South-East 
Asia, Australia, UK and USA (Dangor et al. 2010). Resistance to fluoroquinolones was first 
reported in the late 1980s in the Asia-Pacific regions which led to discontinuation of the use of 




States (US) Centers for Disease Control and Prevention (CDC) removed this class of antibiotics 
from its treatment guidelines in 2007 (Unemo & Shafer 2014). Up until 2002 in KZN, SA, 
isolates were shown to be still susceptible to ciprofloxacin and only in 2003 treatment failures 
were reported with ciprofloxacin resistance (Moodley & Sturm 2005). In KZN, the prevalence 
of ciprofloxacin resistant N.gonorrhoeae increased from 24% in 2004 to 42% in 2005 
(Moodley & Sturm 2005).  Ciprofloxacin resistant N.gonorrhoeae exceeded 40%  in Durban 
by 2005 and approximately 30% in Gauteng which led to use being discontinued in 2008 
(Lewis 2011). In 2004 the prevalence of ciprofloxacin resistance was determined by the 
National STI Surveillance Programme which reported 24% in Durban, 11% in Johannesburg, 
10% in Umtata and 8 and 7% in Pietermaritzburg and Cape Town respectively (Lewis 2007a). 
The National STI Surveillance Programme is run by the National Institute of Communicable 
Diseases STI Reference Centre. Data is collected from sentinel sites across the country from 
primary health care facilities, as well as microbiological surveillance of STIs from 
microbiology departments based at different universities. In 2008 the National Department of 
Health released new guidelines for the treatment of STIs in which oral cefixime became the 
first line treatment of gonococcal infections (Lewis 2011).  
1.6.1.6 Macrolides  
 
This class of antimicrobials was discovered in 1952. Erythromycin, the first drug in this class 
was isolated from Streptomyces erythraeus, a soil microorganism (Unemo & Shafer 2014). The 
synthetic derivative of erythromycin, azithromycin was developed in 1980 (Unemo et al 2013). 
However, this derivative displayed enhanced activity against  N.gonorrhoeae in comparison to 
erythromycin (Unemo et al 2013). Bignell et al. conducted a study to determine the 
effectiveness of azithromycin as a single dose/ monotherapy in the treatment of gonorrhoea. 




cephalosporin rather than monotherapy (Bignell & Garley 2010). This subsequently led to the 
introduction of the drug in dual-antimicrobial therapy regimens  in the USA and Europe 
(Bignell & Unemo 2013; Unemo & Shafer 2014). 
1.6.2 Current antimicrobials used to treat N.gonorrhoeae 
 
1.6.2.1 Cephalosporins  
 
Cephalosporins were discovered by Guiseppe Brotzu in 1948. Cephalosporin compounds were 
isolated from cultures of the fungus Cephalosporium acremonium (CDC 2005). Cefixime 
(oral) and ceftriaxone (injectable) are common cephalosporins recommended for treatment of 
N.gonorrhoeae globally (Unemo & Shafer 2014). Cephalosporins are used in combination with 
metronidazole and doxycycline for the management of discharge causing STIs (National 
Department of Health South Africa 2015) . Reports of resistance to these agents emerged as 
early as 2001 in Japan and there were approximately 30% of  N.gonorrhoeae isolates displaying 
reduced susceptibility to cefixime (Ohnishi et al. 2010; Lewis and Lukehart 2011; Ochiai et al. 
2008). Treatment failures to cefixime has been reported in Japan, Australia, European 
countries, South America and Canada (Unemo et al. 2012; Deguchi et al. 2003; Yokoi et al. 
2007; Allen et al. 2013; Ison et al. 2011; Lewis et al. 2013; Unemo et al. 2011; Unemo et al. 
2010; Ohnishi et al. 2011). Ceftriaxone treatment failures for pharyngeal gonorrhoea have been 
reported in Japan, Australia and some European countries (Ohnishi et al. 2011; Chen et al. 
2013; Read et al. 2013; Unemo et al. 2011; Unemo et al. 2012). Due to the reports of increased 
MIC’s to oral cephalosporins in 2006, cefixime was discontinued as the first line therapy for 
gonorrhoea in Japan (Barry & Klausner 2010). Ceftriaxone is the only remaining agent that 
may be utilized as first line monotherapy. However, due to the emergence of highly resistant 




render monotherapy ineffective (Unemo & Shafer 2014). In 2011, an untreatable strain of 
N.gonorrhoeae was reported in Japan (Shimuta et al. 2013) . This strain was named the  HO41 
strain and documented resistance to all known antibiotics and was  the first extensively drug 
resistant (XDR) strain to be reported (Shimuta et al. 2013). In South Africa, the first report of 
cefixime resistance was identified in 2013 in Gauteng. There were two cases reported among 
men who have sex with men (MSM) patients (Lewis et al. 2013). A study in Eastern Cape 
recently reported decreased susceptibility of N.gonorrhoeae isolates to third generation 
cephalosporins (Faye et al. 2015).    
1.6.3 Future management of N.gonorrhoeae  
 
Numerous microorganisms have evolved and developed resistance over time leading to 
diminished treatment options. This subsequently leads to use of multi drug therapy, which is a 
combination of antimicrobials with different mechanisms of action that decreases the 
propensity of resistance development. The proposed treatment combinations for gonococcal 
infections are one of the cephalosporins and azithromycin (Bignell & Fitzgerald 2011).  Single 
doses of ceftriaxone (250mg IM)  plus azithromycin (1g orally)are currently recommended in 
the 2015 treatment guidelines for STIs (National Department of Health South Africa 2015). 
This dual antimicrobial therapy has been implemented in USA and Europe (CDC 2012) 
(Bignell & Unemo 2013). Where there is documented azithromycin allergy, doxycycline can 
be used in dual therapy with either cefixime or ceftriaxone (Workowski KA 2015). However, 
the cost of implementing dual therapy has serious implications for control programs in poorly 




1.7 Mechanisms of antimicrobial resistance 
Prolonged antimicrobial exposure supports adaptation and survival mechanisms in bacteria. 
N.gonorrhoeae has developed or acquired various mechanisms of resistance to the  
antimicrobials that have been used to treat gonorrhoea over the years (Patel et al. 2011). These 
mechanisms allow N.gonorrhoeae to adapt to and survive in the human host (Unemo & Shafer 
2014). N.gonorrhoeae can undergo transformation by altering its genetic material (Unemo & 
Shafer 2014).  
 N.gonorrhoeae exhibits two types of resistance chromosomally mediated, genetic 
transformation that is responsible for acquiring drug resistance and plasmid mediated 
resistance. The latter is restricted to penicillin and tetracycline, transmitted by conjugation 
(Patel et al. 2011). Plasmid mediated resistance is linked to the blaTEM and tetM genes (Morse 
et al. 1986; Unemo & Shafer 2014).  
1.7.1 Sulfonamide resistance  
 
The mode of action of this antimicrobial is through competition with p-aminobenzoic acid 
(PABA) for the enzyme dihydropteroate synthase (DHPS) that prevents the formation of 
tetrahydrofolate, essential for DNA synthesis (Dillon et al. 2015). Mutations linked to 
sulphonamide resistance were reported in the early 1940’s. A decade later, most N.gonorrhoeae 
isolates were resistant to various sulphonamides (Dillon et al. 2015). Excessive synthesis of 
PABA  dilutes the antimicrobial concentration and may induce alteration in the folP gene 
leading to sulfonamide resistance (Unemo & Shafer 2014). The folP gene encodes the drug 
target DHPS. Alterations in the DHPS target results in lower affinity for sulfonamide agents 




1.7.2 Penicillin resistance 
 
Resistance to penicillin is mediated by genetic mutations and the acquisition of plasmids. 
Penicillin acts by inhibiting the formation of peptidoglycan cross-links in the bacterial cell wall 
through binding of the β-lactam ring to transpeptidase enzymes (penicillin-binding proteins 
[PBPs]) (Unemo & Shafer 2014). High-level penicillin resistance in N.gonorrhoeae is 
mediated by blaTEM-1 plasmids which encode TEM-1 βlactamase (Patel et al. 2011; Unemo & 
Shafer 2014). There have been reports of the global dissemination of N.gonorrhoeae isolates 
that bear the Asian (4.4 MDa) and African (3.2 MDa) plasmids (Tapsall et al. 2014; Speer et 
al. 1992). The African plasmid was more prominent in South Africa (Dangor et al. 2010). 
There are other types of β-lactamase producing plasmids which are Toronto, Rio, Nîmes, New 
Zealand and Johannesburg (Brett 1989; Dillon & Yeung 1989; Gouby et al. 1986; Müller et al. 
2011; Pagotto et al. 2000; Palmer et al. 2000). Strains of PPNG was first reported in 1977 in 
South Africa in Johannesburg and Durban clinics (Hallett et al. 1977; Robins-Browne et al. 
1977). KwaZulu-Natal (KZN) had the highest rates of PPNG during 1999/2000.  
Increase in penicillin resistance was associated with an additive effect of multiple chromosomal 
mutations resulting in altered penicillin binding proteins, increase in the antibiotic efflux 
system and a probable decrease in the antibiotic uptake from the membrane (Patel et al. 2011). 
Mutations in the ponA gene which encodes PBP 1 is involved in high level of penicillin 
resistance (Unemo et al. 2012). PBP 2 is encoded by the penA gene which is the lethal target 
for β-lactam antibiotics (Powell et al. 2009). There has been 5 to 9 mutations in the penA gene 
of penicillin resistant N.gonorrhoeae strains (Ropp et al. 2002). Insertion of an aspartic codon 
(Asp345a) in the penA gene along with downstream mutations causes a reduced affinity of  




associated with a decreased affinity for penicillin (Patel et al. 2011).  
1.7.3 Tetracycline resistance  
 
Tetracycline acts by binding to bacterial ribosome thereby inhibiting protein synthesis (Speer 
et al. 1992). Tetracycline resistance is mediated by genetic mutations and the acquisition of 
plasmids. Chromosomal resistance is linked to mutations in the mtrR, penB and rpsJ genes that 
modify the ribosomal protein that is the target of tetracycline (Unemo & Shafer 2014). Bacteria 
have the ability to develop tetracycline resistance using 3 strategies: (i) by restricting access of 
tetracycline to the ribosome, (ii) modifying the ribosome to prevent effective binding of 
tetracycline and (iii) by producing tetracycline inactivating enzymes. (Speer et al. 1992). The 
first strategy of limiting access of tetracycline is via efflux pump mechanisms. Bacteria that 
carry genes encoding efflux pumps produce a cytoplasmic membrane protein which pump 
tetracycline out of the cell at the same rate as it is  pumped in (Speer et al. 1992). The second 
strategy occurs by bacteria carrying a resistant gene that protects the ribosome and allows the 
ribosome to proceed with protein synthesis. The third strategy is, bacteria carrying a 
tetracycline modification resistant gene that produces an enzyme which chemically modifies 
tetracycline to an inactive form which diffuses out of the cell (Speer et al. 1992). This allows 
protein synthesis to continue.    
Adjunct to these target modifications, an increased and decreased influx of tetracycline due to 
the mtrR and penB  resistance determinants result in enhanced tetracycline resistance (Folster 
et al. 2009; Ohneck et al. 2011; Olesky et al. 2002; Olesky et al. 2006; Zhao et al. 2009).   
The high level of tetracycline resistance in Neisseria gonorrhoeae is mediated by the 
acquisition of the tetM gene carried on a conjugative plasmid (Hakenbeck & Coyette 1998). 




tetracycline (Hakenbeck & Coyette 1998). In 1998/1999, 51% of gonococcal isolates in KZN 
were reported to be tetracycline resistant N.gonorrhoeae (TRNG)  (Dangor et al. 2010). In 
N.gonorrhoeae, the tetM gene has 2 variants viz: the American and Dutch types. Molecular 
epidemiology studies report that the American type may have originated on the African 
continent while the Dutch type may have originated in the Far East. (Turner et al. 1999).  
A study in KZN in 2001, reported the prevalence of the American variant of the gene and no 
occurrences of the Dutch variant of the gene in any of the isolates screened in the study. 
(Moodley et al. 2001). The Dutch variant was detected in Johannesburg amongst clinical 
isolates collected during 2008. However, this variant was not as prevalent as the American 
variant (Fayemiwo et al. 2011).  
1.7.4 Spectinomycin resistance 
 
Spectinomycin acts by inhibiting protein translation by binding to the 30S ribosomal subunit 
of 16S rRNA gene. (Unemo & Shafer 2014). During polypeptide elongation, the interaction of 
spectinomycin with 16S rRNA blocks EF-G catalysed translocation of the peptidyl-tRNA from 
the A site to the P site (Ramakrishnan & White 1992; Sigmund et al. 1984). High level 
spectinomycin resistance in N.gonorrhoeae is linked to Val25 and  K26E alteration in the 30S 
ribosomal protein 5S encoded by the rpsE gene (Unemo et al. 2013).  Low level resistance is 
associated with T24P mutation in 5S. This results in a disruption of binding to 16S rRNA gene 
(Magnus Unemo et al. 2013).  
1.7.5 Quinolone resistance   
 
Fluoroquinolones act by binding to the DNA gyrase and topoisomerase IV enzymes, inhibiting 




topoisomerases are significant for DNA metabolism (Unemo & Shafer 2014). GyrA and GyrB 
subunits make up DNA gyrase, encoded by the gyrA and gyrB genes respectively. 
Topoisomerase IV consists of the ParC and ParE subunits, encoded by the  parC and parE 
genes respectively (Unemo & Shafer 2014). High-level, clinically relevant resistance is 
mediated by alteration of the target sites. Fluoroquinolone resistance is a result of alterations 
in gyrA and parC genes as well as efflux activation and decreased antibiotic cell permeation 
(Patel et al. 2011). Variations in ParC seem to occur in conjunction with presence of mutations 
affecting gyrA (Patel et al. 2011).  
1.7.6 Macrolide resistance  
 
Macrolides act by inhibiting protein synthesis. Resistance to erythromycin and azithromycin is 
mediated by single nucleotide polymorphism (SNP) in 23S rRNA, the binding site of 
macrolides. This leads to either low or high level resistance (Dillon et al. 2015). Efflux pump 
mediated macrolides resistance is mediated by the  mef gene expression (Dillon et al. 2015). 
Mutations in the mtr gene result in an overexpression of an enhanced efflux pump of the 
antibiotic resulting in resistance (Dillon et al. 2015). Low level resistance to azithromycin has 
been reported to occur by the methylation of 23S rRNA by RNA methylases encoded by ermB, 
ermC and ermF (Dillon et al. 2015). Resistance to rifampicin, azithromycin and erythromycin 
is conferred by mutations in the mtrR gene and increased expression of the MtrCDE efflux 
pump system (Tanaka et al. 2006). Azithromycin is not recommended as monotherapy for a 
single dose treatment of gonorrhoea infections due to the concern of rapid emergence and 
spread of resistance and is therefore recommended for use in combination with other drugs 





1.7.7 Cephalosporin resistance  
 
Cephalosprins are β-lactam antimicrobials and with the same mode of action as penicillin 
antibiotics. Mutations in the target PBPs are responsible for resistance to cephalosporins in 
N.gonorrhoeae (Unemo & Shafer 2014). The most common mechanism of resistance to ESCs 
is the acquisition of the penA mosaic allele by horizontal gene transfer (Dillon et al. 2015). 
Mutations/alterations in the penA encoded penicillin binding protein 2 (PBP2) is responsible 
for cefixime resistance. Minor contributions of the mtrR and ponB genes may mediate cefixime 
resistance. Ceftriaxone resistance is linked to all three of these genes (Dillon et al. 2015; 
Ohnishi et al. 2010). The penA gene contains 60 to 70 amino acid alterations. However, it lacks 
the Asp345A insertion that is found in penicillin resistant N.gonorrhoeae  (Lindberg et al. 
2007; Ohnishi et al. 2011). The acquisition of a penA mosaic allele and alterations to the A501, 
G545 and P551 in the transpeptidase/β-lactam binding domain of PBP2 is associated with the 
decreased susceptibility to ceftriaxone (Unemo et al. 2012). The HO41 XDR strain displayed 
high level resistance to cephalosporins (cefixime and ceftriaxone). The strain displayed novel 
penA mosaic allele with 12 additional amino acid alterations (Ohnishi et al. 2011; Unemo & 
Shafer 2014). N.gonorrhoeae F89 is an XDR strain that has emerged from Europe (Unemo et 
al. 2012). These are the first 2 XDR strains that have been reported thus far (Goire et al. 2014). 
The first 2 cases of cefixime resistant N.gonorrhoeae reported in SA showed that they had the 
mosaic penA gene detected by PCR and the full-length sequencing showed that these 2 isolates 
had the identical penA mosaic allele XXXIV (Lewis et al. 2013). This allele has been correlated 
with decreased susceptibility to 3rd generation cephalosporins and cefixime treatment failure in 





1.8. Problem Statement 
Recent literature highlights the major concern regarding effective treatment of N.gonorrhoeae 
in many parts of the world including KZN amid the ever increasing burden of antimicrobial 
resistance. N.gonorrhoeae, a once curable disease has evolved into extensively drug resistant 
forms. Extended spectrum cephalosporins have been advised for treatment of N.gonorrhoeae 
infection. However, reports of resistance to these agents have started to emerge. Due to the 
limitations in treatment options available for the eradication of the disease, we screened isolates 
currently circulating in the KZN province to determine the resistance profiles of the isolates. 
We also explore tetracycline that was previously used to treat N.gonorrhoeae infections and is 
currently part of syndromic management protocols to determine if this drug may be repurposed 
in our setting. 
 
Aims of this study: 
1. To determine the antimicrobial resistance profiles of N.gonorrhoeae isolates circulating 
in KwaZulu-Natal, South Africa.  
2. To investigate if the tetM gene is responsible for high-level tetracycline in Neisseria 
gonorrhoeae 
Objectives 
1. To determine the MIC of the N.gonorrhoeae isolates to azithromycin, cefixime, 
ceftriaxone, ciprofloxacin, ofloxacin, penicillin and tetracycline. 





CHAPTER 2: MATERIALS AND METHODS 
2.1. Ethics Approval and Informed Consent  
The study was approved by the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal UKZN (BE220/13) as well as the Research Committee of the KwaZulu-Natal 
Department of Health (Appendix 6). 
Patients 
Male and female patients 18 years and older were recruited after signed informed consent was 
obtained. A clinical history was taken and the patients were examined. 
2.2. Study Site 
KwaZulu-Natal is one of the most populous Provinces in South Africa with approximately 10.3 
million people. The Province is divided into 11 health districts. The eThekwini and 
uMgungundlovu Districts are home to the 2 largest cities in the Province viz: Durban and 
Pietermaritzburg respectively. The population of these cities account for approximately half of 
the provincial population.  
Patients were recruited from two clinics within these cities:  
The first site, East Boom Clinic is situated in the uMgungundlovu district in Pietermaritzburg. 
It is an urban Community Health Centre (CHC) that services patients from the surrounding 
urban and peri-urban areas. This CHC provides a comprehensive package of services and 
operates 24 hours per day. Patient recruitment occurred from 16 September 2013 to 1 October 




The second site, Umlazi Section D Clinic is situated in the eThekwini district in Umlazi, 
Durban. This clinic also primarily serves an urban and peri-urban community. Patient 
recruitment occurred from 6 October 2014 to 19 December 2014 at this site. 
2.3. Specimen Collection 
Specimens were collected from patients presenting with male urethritis syndrome and vaginal 
discharge syndrome. 
2.3.1. Male patients: 
 
A sterile Dacron® urethral swab was inserted 2 to 3 cm into the urethra and rotated before 
removal.  
2.3.2. Female patients:  
 
A speculum was passed into the vagina to visualise the cervix. An endocervical swab was then 
inserted and rotated in the endocervix before removal.  
The swabs were inoculated onto New York City (NYC) agar plates [prepared with GC agar 
base supplemented with Lincomycin, Colistin, Amphotericin and Trimethoprim (LCAT), yeast 
autolysate (Oxoid, England) and horse blood lysed with saponin (Oxoid, England)]. The 
inoculated plates were placed in a candle extinction jar and transported to the laboratory in the 
Department of Infection, Prevention and Control (IPC) situated at the Nelson R Mandela 
School of Medicine, University of KwaZulu-Natal (UKZN) within 4 hours.  
2.4. Bacterial isolation of N.gonorrhoeae 
In the laboratory, the inoculated plates were streaked using a four-way streak method to obtain 




Following the 48h incubation, plates were examined and a phenotypic assessment was made. 
Presumptive colonies of N.gonorrhoeae were identified based on the colony morphology, 
Gram stain characteristics, a positive oxidase reaction and acid production from glucose. 
2.5. Phenotypic Characterization 
2.5.1. Presumptive identification of N.gonorrhoeae  
 
2.5.1.1. Colony morphology 
 
N.gonorrhoeae colonies appear as grey, smooth, round shaped colonies on selective NYC agar 
plates.  
2.5.1.2. Gram Stain 
 
A Gram stain was performed to confirm the presence of Gram negative diplococci. A 
presumptive colony was picked off using a straight wire and smeared onto a glass slide. The 
smear was heat fixed and stained with crystal violet solution for 20 seconds. The slide was 
gently washed with tap water, followed by staining with iodine for 20 seconds. The slide was 
flooded with acetone for a few seconds and washed off with water. Carbol fucshin solution was 
added onto the slide for 20-50 seconds, the slide was rinsed, blot and air dried. The slide was 
examined microscopically for the presence of pink diplococci. Staphylococcus aureus (ATCC 
25923) (Gram positive) and Escherichia coli (ATCC 25922) (Gram negative) were used as 






2.5.1.3 Oxidase test 
 
An oxidase test was performed to detect oxidase production. A commercial oxidase test strip 
(Merck, SA) was used to determine cytochrome c oxidase activity which is dependent on the 
presence of an intracellular cytochrome oxidase system. The intracellular cytochrome oxidase 
system catalyses the oxidation of cytochrome c by molecular oxygen, which serves as the 
terminal electron acceptor in the organism’s electron transport system. A wooden orange stick 
was used to transfer a few colonies to the pink coated end of the strip. A positive reaction was 
recorded by observing a colour change to a dark blue or purple. Escherichia coli (ATCC 25922) 
and Pseudomonas aeruginosa (ATCC 27853) were used as negative and positive controls 
respectively. 
2.6 Confirmation of N.gonorrhoeae isolates 
Confirmatory tests were performed to differentiate N.gonorrhoeae from other Neisseria 
species. 
2.6.1. Carbohydrate Utilization Test 
 
The carbohydrate utilization test differentiates between Neisseria species based on their 
patterns of acid production from glucose, maltose, lactose and sucrose. These tests were 
conducted on agar plates prepared with GC agar base (Oxoid, England) incorporated with a 
phenol red indicator. The bacterial suspension was prepared by picking off colonies from the 
culture plate and transferring it into Brain Heart Infusion (BHI) broth (Oxoid, England) and 
incubating for approximately 30minutes at 37oC in 5% CO2 until the broth was turbid. 100µl 




Carbohydrate discs were prepared by saturating sterile 9mm antibiotic discs (Lasec, SA) with 
50µl of 20% solutions of glucose, maltose, lactose and sucrose respectively (prepared as 
described in Appendix 1). Individual carbohydrate containing discs were placed onto the agar 
plate in respectively marked quadrants. The plate was incubated for 24h at 37oC in 5% CO2.  
Differentiation of fastidious organisms such as N.gonorrhoeae is based on fermentation 
reactions. Utilization of carbohydrates produces organic acids resulting in a colour change of 
the media from red to yellow. N.gonorrhoeae was identified by its fermentation of glucose 
only.   
Colonies that were confirmed as N.gonorrhoeae were picked off, and sub-cultured onto 
chocolate agar plates to obtain a pure culture for further work up and storage.  
2.7 Storage of Isolates 
All isolates were stored for further testing. Colonies were picked off from the purity plate and 
added to cryovials containing glass beads and BHI broth + 20% glycerol and mixed well by 
inverting the cryovial (preparation as per Appendix 1). The cryovials containing the isolates 
were stored at -80oC in duplicates.   
2.8. Determination of Minimum Inhibitory Concentration (MIC) 
2.8.1 Preparation of antimicrobial solutions 
 
The antimicrobial drugs were purchased from Sigma-Aldrich, USA and stored at temperatures 
recommended by the manufacturer, until use. The minimum inhibitory concentration (MIC) of 
each of the following antimicrobial drugs were obtained for all N.gonorrhoeae isolates: 
Azithromycin (AZITHRO), Cefixime (CEFIX), Ceftriaxone (CEFTRIAX), Ciprofloxacin 




The range of antimicrobial drug concentrations used in the experiments is shown in Table 1. 
The antimicrobial drug stock solutions were prepared in triplicate and the tests were performed 
in triplicate. For each antimicrobial drug, the appropriate amount was weighed out using the 
calculation shown in appendix 2. The antibiotic stocks were prepared as follows: 0.034g of 
azithromycin dissolved in 1ml methanol and topped up to 10ml with distilled water (128mg/L), 
0.032g of cefixime dissolved in 1ml methanol and topped up to 10ml with distilled water 
(128mg/L), 0.032g of ceftriaxone dissolved in distilled water (128mg/L), 0.033g of 
ciprofloxacin dissolved in 1ml acetic acid and topped up to 10ml with distilled water 
(128mg/L), 0.032g of ofloxacin dissolved in 1ml acetic acid and topped up to 10ml with 
distilled water (128mg/L), 0.128g of penicillin dissolved in distilled water (512mg/L) and 
0.033g of tetracycline in 10ml distilled water (128mg/L). All antibiotic solutions were filter 
sterilized using a Millipore 0.22 µm pore size filter unit (Merck Millipore, SA) and aliquoted 
into cryovials with a volume of 1.1ml in each and stored at -20oC until use.  
2.8.2 Preparation of bacterial suspensions 
 
N.gonorrhoeae isolates were retrieved from -80oC storage and cultured onto chocolate agar 
plates and incubated for 24h at 37◦C in 5% CO2. Following the incubation, colonies were 
picked off and a standardised bacterial suspension equivalent to a 0.5 McFarland standard was 
prepared for each isolate as well as the controls.  Controls were selected from WHO reference 
strains, characteristics can be seen in table 1. The WHO reference strains used were WHO F, 






Table 1: Antimicrobial susceptibility phenotypic and genetic (tetM) characteristics of the 
2008 WHO N.gonorrhoeae reference strains  
WHO reference strain 
Characteristics  F G K L O P N 




S1 (0.25) I2 (0.5) S1 
(0.25) 




















































I2 (0.25) PPNG8 
(8) 
Tetracycline  I2 (0.25) TRNG9 
(32) 




---------- Dutch ----------- ----------- -------- ---------- Dutch 
1 S - Susceptible 
2 I – Intermediate 
3 R - Resistant 
4 NS - non susceptible, contains genetic resistance markers but clinical/laboratory correlates are insufficient to 
allow resistance phenotype designation at present 
5 LLR – Low-Level Resistance 
6 HLR – High-level Resistance 
7 CMRNG - chromosomally mediated resistant N.gonorrhoeae 
8 PPNG - penicillinase producing N.gonorrhoeae 
9 TRNG - plasmid mediated tetracycline resistant N.gonorrhoeae 











2.8.3 Minimum Inhibitory Concentration (MIC) using agar dilution method 
 
The agar dilution method is the “gold standard” recommended for MIC determination of 
N.gonorrhoeae isolates. MICs were performed in 90mm petri dishes containing different 
concentrations of antibiotic solution incorporated with GC agar base supplemented with yeast 
autolysate and lysed horse blood (Modified New York City).  
2.8.3.1 Preparation of antimicrobial drug dilutions and plates for agar dilution method 
 
All antimicrobial drug dilutions were done using distilled water. One millilitre of the prepared 
antibiotic stock was added to 9ml of distilled water, mixed well and 5ml was transferred into 
the next tube containing 5ml of distilled water. Twofold serial dilutions were made by 
transferring 5ml from one tube to the next, consecutively and the final 5ml was discarded. 
All antimicrobial dilutions were made in triplicate.  Twenty millilitres (20ml) of the modified 
New York City media was added to each dilution tube (5ml) that gave a final volume of 25ml. 
The media and antibiotic dilution was mixed in the tube by inverting 3 times and poured into 
90mm Petri dishes. The plates were left overnight to set and inoculated the next morning.      
2.8.4 Inoculation of plates  
 
Four hundred microliters (400µl) of each bacterial suspension was transferred into the wells of 
the multipoint inoculator. The 1st well was loaded with a crystal violet dye to serve as a marker 
for orientation of the wells. Wells 2 and 3 were loaded with controls and the remaining wells 
were loaded with the test isolates. The multipoint inoculator transfers approximately 1-2µl of 
each suspension onto the surface of the agar. A drug-free control plate was included as a growth 




highest drug concentrations and ending with a drug-free plate. This is done to avoid carry-over 
of the antibiotic between plates. Plates were incubated for 24h at 37oC with 5% CO2.  
2.8.5 Interpretation of MIC results  
 
Following 24 hours incubation, MIC plates were placed on a multipoint plate reader and the 
MIC results were recorded as the lowest concentration of the antimicrobial drug that inhibited 
growth of the organism on the respective agar plates. Results were interpreted according to the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints 
(2015) for all antimicrobial drugs (Table 2). 
2.9 β-lactamase detection  
This test is done to detect β-lactamase production as N.gonorrhoeae may carry plasmids that 
produce the β-lactamase enzyme. This is a chromogenic cephalosporin method that is widely 
used to detected β-lactamase in N.gonorrhoeae. β-lactamase hydrolyses the β-lactam ring of 
the chromogenic cephalosporin which is nitrocefin and produces a colour change from yellow 
to red. This test is performed by adding one drop of nitrocefin solution (Oxoid, England) onto 
filter paper. Colonies from a pure overnight N.gonorrhoeae culture are picked off and placed 









Table 2: Antimicrobial drug concentrations used for MIC determination 
Antibiotic Concentrations (mg/L) 
Azithromycin  0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8   
Cefixime 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8   
Ceftriaxone 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8   
Ciprofloxacin 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16  
Ofloxacin 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16  
Penicillin 0.007 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 















Table 3: MIC interpretive standards for Neisseria gonorrhoeae according to EUCAST 
Criteria 
MIC breakpoint (mg/L) 
Antimicrobial drug  Susceptible ≤  Resistant > 
Azithromycin  0.25  0.5 
Cefixime  0.125  0.125 
Ceftriaxone  0.125  0.125 
Ciprofloxacin  0.03  0.06 
Ofloxacin  0.125  0.25 
Penicillin  0.06  1 











2.10 Polymerase Chain Reaction (PCR) Amplification  
2.10.1 DNA Extraction 
 
All isolates resistant to tetracycline were used and these were grown on modified New York 
City agar and incubated for 24h at 37oC in 5% CO2. Crude DNA extraction was done using a 
boiling method. This was done by picking off colonies from the culture plate. The colonies 
were inoculated into 1ml BHI broth and vortexed until the suspension was homogenous. This 
suspension was then standardised to a McFarland 1 standard solution (prepared as in Appendix 
2). This was done by aligning the bacterial suspension tube next to the prepared McFarland 1 
standard solution and eyeballing the turbidity. The suspension was centrifuged at 6500rpm for 
5minutes. The supernatant was discarded and the pellet was re-suspended in 500µl of 1 X TE 
buffer. The sample was boiled for 30minutes at 100oC using a heating block. The DNA was 
stored at -20oC until further use.  
2.10.2 Amplification of the tetM gene 
 
PCR amplification was conducted to determine the presence of 2 variants of the tetM gene. The 
assay was performed in final volume of 50µl containing 5µl of the template DNA, 5µl of 
AmpliTaq GOLD LD buffer (10X), 3µl 25mM MgCl2, 1µl deoxy-nucleotides triphosphates 
(dNTPs), 0.45µl of Taq DNA Polymerase (5U/µl) (Life Technologies), 1µl (10pmol) of each 
primer (Universal forward, American reverse and Dutch reverse), and 32.55µl of PCR grade 
water (Roche Diagnostics) refer to Appendix 3 table 11. Primer sequences are shown in table 
3. The cycling protocol utilised was an initial denaturation at 94ºC for 10mins followed by 35 
cycles of denaturation at 94ºC, annealing at 55ºC; extension at 72ºC for 45secs each and a final 




and distilled water was used as a negative control. The expected size of the PCR amplicon for 
the WHO Dutch strain was 443bp. An internal control was designed in our laboratory to serve 
as positive control for the detection of the American variant. A clinical isolate containing the 
American variant, matched to 778bp on an agarose gel was purified and submitted for Sanger 
sequencing. The PCR was conducted in triplicate in 3 separate runs and all amplicons were 
submitted for sequencing. The final sequences of the internal control were aligned to the 
N.gonorrhoeae tetracycline resistant protein (tetM) gene reference sequence. (GenBank 
accession number: AF116348.1) Analysis was done using the Geneious (Biomatters Limited) 
version 8.1 software.  
 
Table 4: Oligonucleotide primer sequences used for the amplification of the tetM gene 








[CTCGAACAAGAGGAAAGC] 778bp Turner A 








[CTCGAACAAGAGGAAAGC] 443bp Turner A 
et al. 1999 








2.10.3 Detection of PCR products by gel electrophoresis  
 
The presence of the tetM gene variants were detected using gel electrophoresis. A 2% agarose 
gel was prepared by mixing agarose with 1x Tris-borate-EDTA buffer (TBE buffer) (Appendix 
3). The agarose was dissolved by heating in a microwave. The solution was cooled to 40-45oC 
and thereafter poured into a gel casting tray secured in a gel casting holder that had a 20 well 
plastic comb attached. The gel was left to solidify at room temperature for 45minutes after 
which the combs and the gel casting tray were removed. The gel was placed in an 
electrophoresis tank filled with 1x TBE buffer. A template was made and placed under a sheet 
of parafilm on which 5ul of the PCR product was mixed with 3µl of gel loading dye containing 
gel red dye (Anatech, SA). A 100bp molecular weight marker XIV (Roche) was included to 
estimate size of PCR products.  The gel was run at 100 volts for 2 hours. The gel was viewed 
under UV illumination using the gel dock and images of the bands were captured using the 
















CHAPTER 3: RESULTS 
3.1 Patient demographic data and Prevalence of Gonorrhoea 
A total of 1220 patients were recruited during the study period from September 2013 to 
December 2014: Boom Street Clinic (n=875) and Umlazi Section D Clinic (n=345). Five 
hundred and six (506) male patients and 714 female patients were recruited. N.gonorrhoeae 
was isolated from 264 (30%) patients at the Boom Street Clinic and 55 (16%) patients from the 
Umlazi Section D Clinic. Overall, there were 319 patients from both clinics from whom 
N.gonorrhoeae was isolated. Two hundred and forty eight (78%) of the positive N.gonorrhoeae 
isolates were from male patients and 71 (22%) isolates were from female patients. The 
dominant age group in male and female patients was the 25-39 year age category. Seventy three 
(29%) of the male patients were between 18-24 years, 164 (66%) were between 25-39 years 
and the remaining 11 patients were over 40 years. In female patients, 30 (42%) were between 
the ages of 18-24 years, 40 (56%) were between 25-39 years and 1 patient (2%) was over the 







Figure 1: Patients with gonorrhoea stratified by Age and Gender 
3.2 MIC Results 
The MIC distribution of the various antimicrobials for N.gonorrhoeae is shown in tables 5, 6, 




Three hundred and seventeen (99%) of the tested isolates were susceptible to cefixime with 
MIC values ranging from ≤0.007mg/L to 0.125mg/L. The remaining 2 (1%) isolates were 
resistant with an MIC value of 0.25mg/L. The distribution of cefixime MIC values stratified 
by year of collection and study site are shown in table 5. In 2014, there was a shift of MIC 
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3.2.1.2 Ceftriaxone 
 
All 319 (100%) tested isolates were susceptible to ceftriaxone with MIC values ranging from 
≤0.007mg/L to 0.125mg/L. The distribution of ceftriaxone MIC stratified by year of collection 
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Ninety two (29%) tested N.gonorrhoeae isolates were susceptible to ciprofloxacin with MIC 
values ranging from ≤0.007mg/L to 0.03mg/L. Four (1%) isolates displayed intermediate 
resistance with an MIC value of 0.06mg/L. The remaining 223 (70%) isolates were resistant 
with MIC values ranging from 0.125mg/L to 8mg/L. The distribution of ciprofloxacin MIC 
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Ninety six of the 319 (30%) tested N.gonorrhoeae isolates were susceptible with MIC values 
ranging from ≤0.007 mg/L to 0.125mg/L. Two isolates (1%) displayed intermediate resistance 
with an MIC value of 0.25 mg/L. The remaining 221 isolates (69%) were resistant with MIC 
values ranging from 0.5mg/L to 8mg/L. The distribution of ofloxacin MIC values stratified by 







Table 8: MIC (mg/L) distribution of N.gonorrhoeae isolates (n=319) for Ofloxacin 
Year of 
collection  
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Fourteen isolates (4%) were susceptible, with MIC values below the susceptibility breakpoint 
of 0.25 mg/L. Eighty eight (28%) displayed intermediate resistance with an MIC value of 0.5. 
The remaining 217 isolates (68%) were resistant with MIC values ranging from 1mg/L to 
4mg/L. The distribution of azithromycin MIC values stratified by year of collection and study 




Table 9: MIC (mg/L) distribution of N.gonorrhoeae isolates (n=319) for Azithromycin 
Year of 
collection  
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Five of the 319 (2%) tested N.gonorrhoeae isolates were susceptible with an MIC value of 
≤0.06mg/L. One hundred and five isolates (33%) displayed intermediate resistance with MIC 
values ranging from 0.125 mg/L to 1 mg/L. The remaining 209 isolates (65%) were resistant 
with MIC values ranging from 2mg/L to 8mg/L. The distribution of penicillin MIC values 
stratified by year of collection and study site are shown in table 10. 
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All 319 (100%)  N.gonorrhoeae isolates were resistant to tetracycline with MIC values > 
16mg/L. There were no susceptible isolates. The distribution of tetracycline MIC values 
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3.3 Molecular characterization of tetracycline resistance (PCR results) 
The tetM gene was detected in 293 (92%) of the 319 isolates that were resistant to tetracycline. 
Two hundred and sixty four of the 293 (90%) isolates had the American variant of tetM gene 
and 29 (10%) had the Dutch variant of tetM gene. Twenty six (8%) of the 319 isolates did not 
harbour any tetM gene. The distribution of the 2 variants of the gene between the 2 study sites 
was similar (figure 2). Figure 3 shows a picture of the gel electrophoresis run with both types 
of the tetM gene. The sequencing alignment of the internal control for the American variant of 
the tetM gene and detailed patient demographic data, complete MIC data and PCR results are 
attached in the appendices. 




















Figure 2: Distribution of tetM variants amongst tetracycline resistant N.gonorrhoeae 
isolates at the two clinical sites 
 
Figure 3: Detection of the tetM gene in clinical isolates of N.gonorrhoeae 
Lane 1: Molecular weight marker XIV 100bp (Roche) 
Lane 2: American Control (778bp) 
Lane 3: Dutch Control WHO N (443bp) 
Lane 4: Negative Control  
Lanes 5-8, 11, 13, 14 and 17-20: Clinical isolates of N.gonorrhoeae (American) 
Lanes 9, 10, 12 and 16: Clinical isolates of N.gonorrhoeae (Dutch) 








CHAPTER 4: DISCUSSION 
 
The emergence of drug resistant strains of N.gonorrhoeae is a growing public health concern. 
Maintaining effective treatment of gonococcal infections remains a challenge given the ability 
of N.gonorrhoeae to rapidly acquire resistance mechanisms (Bignell & Garley 2010). Routine 
surveillance and drug susceptibility testing of N.gonorrhoeae does not feature on STI control 
and management programs in the country. Such surveillance is limited to research settings and 
STI data is mainly acquired from patients visiting ante-natal clinics. In an attempt to understand 
the dynamics of antimicrobial resistance amongst N.gonorrhoeae isolates currently circulating 
in our setting, we collected clinical specimens from 2 study sites in the two largest cities in 
KZN over a 2 year period and screened isolates for resistance to various antimicrobials. We 
included antimicrobials previously used for treatment, as well as the currently recommended 
for the management of infections with N.gonorrhoeae. 
The results of this study confirm that majority of the isolates are still resistant to antibiotics that 
were historically used to treat gonorrhoea viz: penicillin, tetracycline and the fluoroquinolones. 
Penicillin has been extensively used in the treatment of gonorrhoea infections. The evolution 
of penicillin resistance and its resistant determinants has been well established globally (Elwell 
et al. 1977). Our data supports the trends that have been reported over the past two decades 
which have demonstrated an increase in number of gonococcal strains resistant to penicillin 
(Amies 1967). In this study, 98% of the isolates displayed MIC values in the intermediate or 
resistant range for penicillin. Sixty percent (60%) of the N.gonorrhoeae isolates in this study 
carry plasmids which produce the β-lactamase enzyme and are resistant to penicillin. The 




plasmid could be using other mechanisms of resistance. These isolates could possibly have the 
penA or ponA genes present that are responsible for penicillin resistance or mutations in these 
genes. Penicillin resistance is also due to the acquisition of plasmids which could be present in 
these isolates. However PCR was not done to confirm the presence of these genes or plasmids. 
Ciprofloxacin resistance was reported in 60% of patients with gonorrhoea in a Durban clinic 
in 2006 compared to 42% in 2005 (Moodley & Sturm 2005). Similar trends were reported for 
a Johannesburg clinic (Lewis 2007). Ciprofloxacin was introduced into the treatment 
guidelines in KZN in 1995 and was discontinued following reports of decreased susceptibility 
to the drug (Lewis & Marumo 2009). This was in keeping with Asian and European countries 
that had removed ciprofloxacin as part of first line treatment protocols for gonorrhoea due to 
the high levels of resistance (Unemo & Shafer 2011). Our data supports the study by Moodley 
et al, 2001, that demonstrated increased MICs to these antimicrobial drugs. In the current study, 
70% of the isolates displayed resistance to the fluoroquinolones.  
Azithromycin has been used to treat gonococcal infections in many countries. A previous study 
by Moodley et al, 2001 showed that even though azithromycin was not in the recommended 
treatment guidelines in South Africa at the time, there was an alarming increase in resistance 
to the drug (Moodley et al. 2001). This was most likely due to antibiotic pressure from the 
widespread use of this drug for other infections. Our study supports this finding as our MIC 
results for azithromycin show that 68% of the isolates are resistant to this antimicrobial drug. 
High-level resistance (MIC ≥256mg/L) to azithromycin was described in Scotland (Palmer et 
al. 2008), England (Chisholm et al. 2010), Argentina (Galarza et al. 2010), Italy (Starnino & 
Stefanelli 2009), United States (Katz et al. 2012) and Sweden (Unemo et al. 2013). However 




The isolates in the current study displayed high-level tetracycline resistance (MIC ≥16 mg/L), 
4 to 5 fold higher than the current recommended breakpoint for the drug. Three hundred and 
seven of the 319 isolates displayed an MIC value of ≥32 mg/L and the remaining 12 isolates 
had an MIC value of 16 mg/L. In South Africa, high-level tetracycline resistance was first 
reported in Bloemfontein in 1994 (Chalkley et al. 1997). A previous study conducted in 1999 
in KZN reported that 67% isolates had a MIC to tetracycline ≥16mg/L (Moodley et al. 2001). 
The results of the current study indicate that N.gonorrhoeae isolates in our setting have evolved 
and are fully resistant to tetracycline. Genetic mutations, acquisition of plasmids and 
modifications of drug targets have allowed for N.gonorrhoeae to become resistant to 
tetracycline. Our study also supports the findings of many other studies that have shown an 
increase in tetracycline MIC over the years (Moodley et al. 2001; Dangor et al. 2010). 
High-level tetracycline resistance  attributed to the acquisition of  the tetM gene which protects 
the ribosome from tetracycline and therefore renders the drug ineffective (Moodley et al. 2001). 
In an attempt to characterize the molecular basis for high level tetracycline resistance, we 
screened isolates for the presence of either the American or Dutch variant of the tetM gene. In 
keeping with previous findings, the tetM gene was detected in 92% of the isolates (Van Dyck 
et al. 1992; Moodley et al. 2001). Furthermore, our data shows the predominance of the 
American variant of the tetM gene carried by 90% of the isolates. This aligns to the premise 
that the American variant of the tetM originated on the African continent (Turner et al. 1999). 
This is further supported by reports from Botswana and Namibia in Southern Africa which 
attribute high level tetracycline resistance to the American variant of the tetM gene (Chalkley 
et al. 1995). Previous reports suggest that the American variant is widely distributed in South 
Africa (Chalkley et al. 1997). Previous reports have shown high numbers of the Dutch variant 




We report the presence of the Dutch variant in 10% of isolates. Although the Dutch variant is 
not commonly seen in the country, it is slowly emerging and circulating (Fayemiwo et al. 2011; 
Chalkley et al. 1997). To the best of our knowledge, this is the first report of the Dutch variant 
of the tetM gene in KZN. Both variants displayed similar MIC values for tetracycline and were 
present in isolates from both study sites. 
Twenty six isolates representing 8% of the tetracycline resistant isolates displayed high level 
tetracycline resistance in the absence of any of the tetM genes. This indicates the possibility of 
an alternate mechanism of tetracycline resistance such as an efflux pump. Interestingly, this is 
the first report of isolates displaying high level tetracycline resistance in the absence of the 
tetM gene. Identification of alternate mechanisms of resistance or alternate targets will provide 
invaluable information regarding tetracycline resistance. Concerns have been raised regarding 
the transfer of the tetM gene between various organisms as the gene is carried on a plasmid. 
Due to the possible interaction between chlamydial and gonococcal infections it is questionable 
whether tetracycline can still be used for the treatment chlamydial of infections. 
The cephalosporins are the only remaining class of antibiotics that are available for gonorrhoea 
monotherapy. Ceftriaxone and cefixime are recommended for treatment of this infection. Our 
results showed that 2 isolates were resistant to cefixime, whilst none displayed resistance to 
ceftriaxone. However, we did note a gradual increase in the MIC values of gonococcal isolates 
over the 2 year collection period. In 2013, all isolates that were collected were susceptible to 
both cephalosporins with MIC values of ≤ 0.007mg/L.  In 2014, the isolates displayed a gradual 
increase in MIC values. Whether the increase in MIC values indicates in vivo clinical resistance 
requires further elucidation of the mechanisms mediating resistance to these drugs. To date, we 




treatment failures have been reported in 2 homosexual men in Johannesburg (Lewis et al. 
2013). 
A significant factor contributing to the emergence and spread of resistant forms of gonococcal 
infections is the pressure created by syndromic management of STIs. South Africa and many 
resource-limited settings apply syndromic management for the treatment of STIs. Syndromic 
management involves treating patients based on signs and symptoms in the absence of a 
confirmed laboratory diagnosis. Reports show that only 13% of symptomatic STIs are cured 
with the current STI services in KZN (White et al. 2008; Mlisana et al. 2012).  Drug pressure 
from these empiric regimens has resulted in widespread resistance (Moodley, Pillay, et al. 
2001). There have been conflicting reports regarding the utility of syndromic management. 
Whilst it aims to ensure that the patient receives quality treatment at the first visit to the 
healthcare facility without the delay of a laboratory diagnosis this approach underestimates the 
prevalence of STIs, especially in the cases of asymptomatic infection (Grosskurth et al. 2000; 
Kamali et al. 2003; Gregson et al. 2007).  
A study by White et al. 2008 estimated the effectiveness of treatment of STIs in rural KZN 
before and after the implementation of syndromic management in South Africa in 1995. This 
study showed that after the introduction of syndromic management the prevalence of STIs 
especially chlamydia and gonorrhoea did not decrease but increased (White et al. 2008). 
Syndromic management of STIs is seen as a cost-saving HIV prevention strategy however due 
to the emergence of high-levels of drug resistance in N.gonorrhoeae and the interaction of the 
HIV epidemic, the utility of syndromic management requires urgent re-consideration in our 
setting that has a high HIV incidence (White et al. 2008). Reports of increasing STI resistance 




might not be the most effective solution for the management of STIs. The most recent new STI 
guidelines (CDC 2015) advocate inclusion of diagnostic testing algorithms to improve patient 
outcomes. Whilst the individualized approach may offer a great improvement in the 
management of STIs, it might not be widely implemented due to financial constraints 
especially in developing countries.   
The emergence of N.gonorrhoeae displaying resistance to most antimicrobials previously and 
currently available for the treatment of gonococcal infections is a major concern. Such strains 
have been defined as XDR strains displaying resistance to 2 or more of the classes that are 
generally recommended for treatment gonorrhoea or 3 or more of the classes that are less 
frequently recommended for treatment (Goire et al. 2014). The first 2 XDR strains displaying 
high level antimicrobial resistance to most agents including the cephalosporins were described 
in Japan (Ohnishi et al. 2011) and Europe (Magnus Unemo et al. 2012). These were identified 
in 2 high risk populations which included a commercial sex worker and homosexual male. 
Detection of such strains has naturally led to the implementation of dual-therapy regimens. To 
date, dual-therapy has been implemented in the United States (CDC 2012), United Kingdom 
(Bignell & Fitzgerald 2011) and throughout Europe (Bignell & Unemo 2013). Dual-therapy 
regimens mainly includes the combined use of azithromycin and ceftriaxone. However, due to 
the decreased susceptibility of N.gonorrhoeae to the cephalosporins and previously reported 
azithromycin resistance, dual-therapy is not an effective long term solution.  
We caution against the application of this combination in our setting for 2 main reasons. Firstly, 
68% of the isolates in the current study display resistance to azithromycin. Secondly, our 
isolates show an increase in MIC for the cephalosporins over the 2 year collection period. In 
addition to these, reports of cefixime resistance in Johannesburg raise the concern of the spread 




provide evidence that empiric use of this combination in our setting will only drive further 
resistance in N.gonorrhoeae and will be disastrous from a public health perspective. Drug 
susceptibility, where possible should be conducted prior to the initiation of treatment. 
The increase in resistance to tetracycline and increasing MIC to cephalosporins highlights the 
urgent need for routine surveillance and drug susceptibility monitoring systems in the country. 
Data from research settings does not provide a universal representation of the drug resistance 
problem for the country. Furthermore, discrepancies in reporting guidelines from EUCAST 
and CLSI are potentially underestimating or overestimating resistance. In both cases, 
inadequate treatment contributes to the burden of drug resistance. In the current study, we have 
utilized EUCAST breakpoints for all drugs. CLSI guidelines are widely used however; their 
breakpoints are higher than EUCAST guidelines. This results in misclassification of a 
proportion of resistant isolates. Forty five (45) resistant isolates would have been misclassified 
as susceptible if CLSI breakpoints were used. Ideally genotypic characterization should be 
conducted to confirm and correctly identify resistant isolates from those that are susceptible. 
However this would only apply to known mutations associated with resistance. Correlations 
between phenotypic and genotypic data should be applied in order to produce uniform 
guidelines that should be implemented globally. 
New rapid diagnostic assays offer a ray of hope. The Cepheid GeneXpert® Chlamydia 
trachomatis (CT)/Neisseria gonorrhoea (NG) test is capable of producing test results in 90 
minutes. This technology can provide testing whilst the patient is still present at the clinic, 
eliminating treatment delays and inappropriate results. If this is implemented in a clinical 
setting it will reduce over prescribing of antibiotics when and if not necessary and assist with 
syndromic management. Furthermore, the cartridge based test can be applied to the same 




major advantage in South Africa as the testing platform has been implemented throughout the 
country as part of the national tuberculosis control programme. The ThermoFisher Open-Array 
real-time PCR based test has the ability to detect multiple infections simultaneously in just 2 
hours. This test however, will require expertise and training which may not be ideal to be used 
as a rapid diagnostic but rather in the research setting for surveillance studies. This system 
could be a better option than the real-time multiplex PCR because not only does it have high 
specificity but it also uses less reagents that minimizes costs.  
In conclusion, the results of this study provide compelling evidence of increased antimicrobial 
drug resistance in clinical isolates of N.gonorrhoeae currently circulating in KZN. This study 
has important implications for the local STI control programme as it highlights the looming 
crisis of multidrug resistant N.gonorrhoeae strains and the urgent need for routine surveillance 
of these organisms. We have shown that empirical dual-therapy with azithromycin and a 3rd 
generation cephalosporin might not be an option in our setting. Furthermore, in a resource 
limited setting like South Africa, the cost of new drugs and dual-therapy will pose an additional 
financial burden, whilst driving antibiotic resistance. We support the judicious use of 
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Primary isolation agar plates 
1.1 New York City Agar  
 
Weigh out 36g GC agar base (Oxoid, England) and dissolve in 850ml of distilled water, 
autoclave for 15mins at 121oC. Dissolve supplements 2 X yeast autolysate (Oxoid, England) 
by adding 15ml of distilled autoclaved water into each vial. Dissolve 2x LCAT supplement 
(Oxoid, England) by adding 5ml of distilled autoclaved water to each vial and filter sterilising 
through a 0.2µm Millipore filter. Lyse horse blood using saponin (Sigma-Aldrich, USA). Pour 
100ml of horse blood into autoclaved bottle.  Weigh out 0.5g of saponin and dissolve in 10ml 
of distilled autoclaved water, filter through Millipore and add to blood for 30mins. Supplements 
and blood are added when media is cooled to 55 oC. 
1.2 Candle Extinction Jar 
 
A jar with a lid that seals tightly is used to create a humid atmosphere for the transportation of 
the inoculated agar plates. Paper towel is moistened with water and placed at the bottom of the 
jar. Once plates are placed inside the jar, a candle is lit inside and closed with the lid of the jar.  
1.3 Chocolate agar plates (subculture for storage of isolates) 
 
Weigh out 39g of Columbia Blood Agar Base (Oxoid, England) and dissolve in 1000ml of 
distilled water. Autoclave for 15 minutes at 121 oC. Once autoclave complete, transfer flask to 
waterbath and pour 50ml of horse blood immediately around 80 oC. Mix well, allow to cool 




1.4 Preparation of 0.5% phenol red solution 
 
Weigh out 0.5g of phenol red powder and dissolve in 100ml of distilled water. Autoclave for 
15 minutes at 121 oC. 
1.4.1 GC sugar plates for acid production 
 
Weigh out 36g of GC agar base (Oxoid, England) and dissolve in 1000ml of distilled water, 
add 5ml of a 0.5% phenol red solution mix well. Adjust pH to 7.6 and autoclave for 15 minutes 
at 121 oC.    
1.4.2 Preparation of 20% sugar solutions for glucose, maltose, lactose and sucrose 
 
Weigh out 20g of each sugar and dissolve in 100ml of distilled water. Filter each sugar through 
Millipore filter size 0.2µm (Merck, SA) into autoclaved bottles.  
Autoclave 9mm antibiotic discs (Lasec, SA) and separate into 4 Petri dishes for each sugar. 
Saturate discs with 50µl of each sugar solution and allow to dry at 37 oC overnight.  
1.5 Storage media (BHI + 20% glycerol medium) for isolates 
 
Weigh 3.7g of BHI powder (Oxoid, England), add 20ml glycerol and add 80ml distilled water. 
Autoclave for 15 minutes at 121 oC. Allow to cool and keep at 4 oC.  
Dispense glass beads into bottles and autoclave for 15 minutes at 121 oC.  
1.6 Preparation of storage vials 
 







MIC media and antimicrobial stock solutions preparation 
2.1 Preparation of modified New York City agar for antimicrobial susceptibility testing 
of MICs 
 
Weigh out 36g GC agar base (Oxoid, England) and dissolve in 860ml of distilled water, 
autoclave for 15mins at 121oC. Dissolve supplements 2 X yeast autolysate (Oxoid, England) 
by adding 15ml of distilled autoclaved water into each vial. Pour 100ml of horse blood into 
autoclaved bottle.  Weigh out 0.5g of saponin and dissolve in 10ml of distilled autoclaved 
water, filter through Millipore and add to blood for 30mins. Supplements and blood are added 
when media is cooled to 55 oC. 
2.2 Preparation of 0.5 McFarland Standard 
 
0.5 McFarland standard is prepared by mixing 0.05 mL of 1.175% barium chloride dihydrate 
(BaCl2•2H2O), with 9.95 mL of 1% sulfuric acid (H2SO4). 
Confirm with spectrophotometer at 625nm the reading should range from 0.08 to 0.10  
 
2.2.1 Preparation of McFarland No. 1 Standard 
 
0.5 ml of concentrated H2SO4  (Merck, SA) was added to 49.5 ml of triple distilled water, to 
make a 1 % H2SO4 solution. 0.175g of BaCl2.2H2O (Sigma-Aldrich, USA) was added to 10 ml 
of triple distilled water to make a 1 % BaCl2.2H2O solution. 
Thereafter 4.95 ml of 1 % H2SO4 solution was combined with 50 µl of 1 %  BaCl2.2H2O 
solution. The tube containing the McFarland 1 suspension was wrapped in foil and stored away 




2.3 Antibiotic stock solutions  
 
Weight of powder = [highest concentration (µg/ml)] x [volume (ml)] 
 (potency µg/mg) 
                               = powder weight (µg/ml) 
Diluent required = [weight of powder (µg/ml)] x [volume (ml)] 
 
2.4 BHI broth for culture suspensions 
 
Weigh out 3.7g of BHI powder (OXOID, England), add 100ml of distilled water and mix 













PCR master mix reagents and cycling conditions 
 
All three primers used were from publication Turner et al. 1999 and synthesized for this study 
by Applied Biosystems. 
Add 100µl PCR grade water to lyophilized primers to reconstitute. Vortex until dissolved and 
quick spin.  
3.1 Working solution of primers (10pmol) 
 














Table 12: PCR MasterMix for tetM gene variants 
Gene MasterMix (1X Reaction) 
  
tetM 1. AmpliTaq GOLD LD Buffer (10X 5µl 
 2. MgCl2 (25mM) 3µl 
 3. dNTPs Mix 1µl 
 4. Primer Universal Forward (10pmol) 1µl 
 5. Primer American Reverse (10pmol) 1µl 
 6. Primer Dutch Reverse (10pmol) 1µl 
 7. Enzyme (5U) 0.45µl 
 8. PCR Grade Water 32.55µl 
 Total Volume for 1X reaction 45µl 
 
 







3.2 PCR Cycling Conditions 
 
35 cycles of Denaturation, Annealing and Extension 
Cycling condition  Time and temperature  
Initial Denaturation                                                              10 minutes at 94oC// 
Denaturation                 45 seconds at 94oC 
Annealing    45 seconds at 50oC 
Extension     45 seconds at 72oC 
Final Extension 5 minutes at 94 oC 
Hold 4 oC  
 
3.3 Agarose gel electrophoresis  
 
3.3.1 10X TBE Buffer 
 
Trizma base (Sigma-Aldrich, USA) 108g  
Boric acid (Sigma-Aldrich, USA) 55g  
EDTA (Sigma-Aldrich, USA) 9.3g  







3.3.2 1X TBE Buffer 
 
Add 100ml of 10X TBE buffer to 900ml of distilled water.  
 3.3.3 2% agarose gel (150ml) 
 
Agarose powder (LONZA, USA)            3g 
1X TBE buffer                                   150ml 
The agarose powder was weighed and added to a flask containing 1X TBE buffer. The mixture 
was boiled in a microwave until the powder was dissolved.  
The agarose and TBE solution was allowed to cool to about 45oC and poured into a casting gel 
tray secured in a tray holder that had a 20 well comb attached. The gel was allowed to set at 
room temperature for 40-55minutes before removing the combs.   
 
3.3.4 Gel loading dye  
 
Glycerol    50g 
1M Tris/HCl, pH 7.5   5ml 
100mM EDTA    5ml 
Bromophenol blue (Sigma-Aldrich, USA)   0.05g 
10mg/ml RNase    300µl 
Weigh out the reagent powders and their required amounts. Measure the required volumes of 




100oC water bath to dissolve. Store at 4 oC for no longer than one year.  
980ul was dispensed into cryovials and stored. 20ul of Gel Red (Biotium) was added to the 
980ul of gel loading dye.  
 





Raw data  
 
ISOLATE NUMBER 
 PEN CIPRO OFLOX TET CEFIX CEFTR AZITHRO AGE GENDER tetM  
1  0.25 4 4 ≥32 ≤0.007 ≤0.007 2 19 M A 
2  0.25 ≤0.007 0.015 ≥32 ≤0.007 ≤0.007 2 28 M A 
3  0.25 4 4 ≥32 ≤0.007 ≤0.007 0.5 21 M A 
4  8 4 4 ≥32 ≤0.007 ≤0.007 4 24 M A 
5  8 0.015 0.015 ≥32 ≤0.007 ≤0.007 1 28 M A 
6  0.125 0.03 0.015 ≥32 ≤0.007 ≤0.007 2 29 M A 
7  0.5 0.5 0.5 ≥32 ≤0.007 ≤0.007 0.5 33 M A 
8  4 4 4 ≥32 ≤0.007 ≤0.007 1 27 M A 
9  0.125 0.25 ≤0.007 ≥32 ≤0.007 ≤0.007 1 30 M A 
10  0.5 0.03 0.015 16 ≤0.007 ≤0.007 1 25 M A 
11  4 8 8 ≥32 ≤0.007 ≤0.007 4 30 M N 
12  8 4 4 ≥32 ≤0.007 ≤0.007 1 21 M D 
13  8 4 4 ≥32 ≤0.007 ≤0.007 2 40 M A 
14  8 ≤0.007 0.015 ≥32 ≤0.007 ≤0.007 0.5 18 M A 
15  4 4 4 ≥32 ≤0.007 ≤0.007 1 24 M A 
16  8 0.03 0.015 ≥32 ≤0.007 ≤0.007 0.5 44 M N 
17  2 4 4 ≥32 ≤0.007 ≤0.007 0.25 21 M A 
18  0.125 0.015 0.015 ≥32 ≤0.007 ≤0.007 1 23 M A 
19  8 4 4 ≥32 ≤0.007 ≤0.007 2 33 M D 




21  8 2 4 ≥32 ≤0.007 ≤0.007 2 37 M A 
22  0.5 4 8 ≥32 ≤0.007 ≤0.007 2 35 M A 
23  8 1 2 ≥32 ≤0.007 ≤0.007 1 30 M A 
24  4 1 2 ≥32 ≤0.007 ≤0.007 1 33 M A 
25  8 0.06 0.015 ≥32 ≤0.007 ≤0.007 0.5 42 M A 
26  1 1 2 ≥32 ≤0.007 ≤0.007 2 25 M N 
27  4 0.03 0.015 ≥32 ≤0.007 ≤0.007 0.5 29 M A 
28  8 4 4 ≥32 ≤0.007 ≤0.007 1 27 M A 
29  2 1 1 ≥32 ≤0.007 ≤0.007 1 22 M A 
30  0.5 4 4 ≥32 ≤0.007 ≤0.007 1 28 M A 
31  2 4 8 ≥32 ≤0.007 ≤0.007 0.5 38 M A 
32  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 31 M A 
33  4 4 8 ≥32 ≤0.007 ≤0.007 2 30 M D 
34  8 0.06 0.015 ≥32 ≤0.007 ≤0.007 0.5 26 M D 
35  4 0.03 0.015 16 ≤0.007 ≤0.007 0.25 21 M N 
36  8 0.03 0.015 ≥32 ≤0.007 ≤0.007 0.5 25 M A 
37  0.5 1 2 ≥32 ≤0.007 ≤0.007 1 32 M A 
38  1 0.03 4 ≥32 ≤0.007 ≤0.007 2 30 M A 
39  0.5 4 8 ≥32 ≤0.007 ≤0.007 2 22 M A 
40  0.25 4 8 ≥32 ≤0.007 ≤0.007 1 30 M A 
41  0.125 0.25 2 ≥32 ≤0.007 ≤0.007 2 24 M A 
42  8 4 4 ≥32 ≤0.007 ≤0.007 1 30 M A 
43  8 0.5 0.5 ≥32 ≤0.007 ≤0.007 0.5 23 M N 
44  8 0.03 0.015 ≥32 ≤0.007 ≤0.007 0.5 29 M A 
45  1 4 4 ≥32 ≤0.007 ≤0.007 2 28 M D 
46  0.125 4 4 ≥32 ≤0.007 ≤0.007 2 21 M A 
47  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.25 36 M A 




49  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 28 M A 
50  1 4 4 ≥32 ≤0.007 ≤0.007 2 31 M A 
51  8 ≤0.007 0.03 ≥32 ≤0.007 ≤0.007 0.5 33 M A 
52  0.25 0.125 0.25 ≥32 ≤0.007 ≤0.007 2 26 M A 
53  0.06 0.06 0.03 ≥32 ≤0.007 ≤0.007 0.5 30 M A 
54  8 1 2 ≥32 ≤0.007 ≤0.007 1 28 M A 
55  0.125 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.125 21 M A 
56  0.125 0.03 0.015 ≥32 ≤0.007 ≤0.007 1 27 M N 
57  8 4 4 ≥32 ≤0.007 ≤0.007 2 31 M D 
58  8 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 29 M A 
59  0.5 4 4 ≥32 ≤0.007 ≤0.007 1 37 M A 
60  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 26 M A 
61  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 27 M A 
62  1 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 29 M A 
63  4 4 4 ≥32 ≤0.007 ≤0.007 1 30 M A 
64  8 1 4 ≥32 ≤0.007 ≤0.007 0.5 35 M A 
65  1 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 35 M A 
66  8 4 4 ≥32 ≤0.007 ≤0.007 1 21 F D 
67  0.06 ≤0.007 0.015 ≥32 ≤0.007 ≤0.007 1 22 M A 
68  0.125 4 4 ≥32 ≤0.007 ≤0.007 2 23 M A 
69  0.06 4 4 ≥32 ≤0.007 ≤0.007 2 23 F N 
70  0.25 4 4 ≥32 ≤0.007 ≤0.007 2 29 M A 
71  8 4 4 ≥32 ≤0.007 ≤0.007 1 26 M D 
72  0.06 0.06 0.03 ≥32 ≤0.007 ≤0.007 0.5 18 M A 
73  1 0.015 0.06 16 ≤0.007 ≤0.007 2 30 F N 
74  4 4 4 ≥32 ≤0.007 ≤0.007 1 27 M D 
75  8 0.5 1 ≥32 ≤0.007 ≤0.007 1 35 M A 




77  4 4 4 ≥32 ≤0.007 ≤0.007 1 30 F D 
78  0.5 0.03 0.03 ≥32 ≤0.007 ≤0.007 1 29 M A 
79  2 0.25 0.5 16 ≤0.007 ≤0.007 0.25 31 F A 
80  8 1 2 ≥32 ≤0.007 ≤0.007 0.5 27 M A 
81  0.06 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 30 M N 
82  2 1 1 16 ≤0.007 ≤0.007 1 38 M A 
83  0.125 0.5 1 ≥32 ≤0.007 ≤0.007 0.5 30 F A 
84  8 1 2 ≥32 ≤0.007 ≤0.007 1 19 M A 
85  4 4 4 ≥32 ≤0.007 ≤0.007 1 28 F D 
86  1 4 4 ≥32 ≤0.007 ≤0.007 2 28 M A 
87  0.125 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 49 M A 
88  8 0.5 1 ≥32 ≤0.007 ≤0.007 0.5 21 M A 
89  4 4 4 ≥32 ≤0.007 ≤0.007 0.5 32 M D 
90  0.5 2 4 ≥32 ≤0.007 ≤0.007 1 31 M A 
91  8 1 2 ≥32 ≤0.007 ≤0.007 0.125 25 M A 
92  8 4 4 ≥32 ≤0.007 ≤0.007 1 33 M A 
93  4 4 4 ≥32 ≤0.007 ≤0.007 0.5 29 M A 
94  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 20 M A 
95  4 4 4 ≥32 ≤0.007 ≤0.007 0.5 28 M D 
96  8 0.015 0.03 ≥32 ≤0.007 ≤0.007 2 24 M D 
97  8 4 4 ≥32 ≤0.007 ≤0.007 1 22 F A 
98  2 1 2 ≥32 ≤0.007 ≤0.007 1 18 M A 
99  8 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 25 M A 
100  1 0.03 0.03 ≥32 ≤0.007 ≤0.007 0.5 37 M N 
101  1 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 35 M A 
102  8 1 2 ≥32 ≤0.007 ≤0.007 2 32 M A 
103  0.5 4 4 ≥32 ≤0.007 ≤0.007 1 27 M A 




105  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 2 20 M A 
106  8 0.015 0.125 ≥32 ≤0.007 ≤0.007 1 32 M A 
107  0.125 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 32 M N 
108  8 1 1 ≥32 0.06 0.03 0.5 28 M A 
109  4 1 2 ≥32 0.06 0.03 1 40 M A 
110  0.5 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 2 25 M A 
111  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 28 M A 
112  2 ≤0.007 ≤0.007 ≥32 0.03 ≤0.007 0.5 29 M A 
113  8 0.25 0.5 ≥32 ≤0.007 ≤0.007 1 26 M A 
114  2 2 4 ≥32 0.06 0.015 0.5 32 F A 
115  0.25 4 4 ≥32 0.015 0.03 1 28 M A 
116  0.5 4 4 ≥32 0.03 0.015 1 27 F A 
117  8 ≤0.007 ≤0.007 ≥32 0.015 0.015 1 23 M A 
118  8 2 4 ≥32 ≤0.007 ≤0.007 1 33 M A 
119  0.25 4 4 ≥32 ≤0.007 ≤0.007 0.5 29 F A 
120  0.5 4 4 ≥32 ≤0.007 ≤0.007 2 37 M A 
121  0.125 4 4 ≥32 ≤0.007 ≤0.007 1 76 F N 
122  2 ≤0.007 ≤0.007 ≥32 ≤0.007 0.015 0.5 29 M A 
123  0.125 ≤0.007 ≤0.007 ≥32 0.06 0.015 1 32 F A 
124  0.25 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 24 F A 
125  8 0.015 0.015 ≥32 0.015 ≤0.007 2 18 M N 
126  4 4 8 ≥32 ≤0.007 0.015 0.5 21 M A 
127  2 4 4 ≥32 ≤0.007 ≤0.007 2 35 M A 
128  8 1 1 ≥32 ≤0.007 ≤0.007 2 21 F A 
129  0.125 4 4 ≥32 ≤0.007 ≤0.007 4 20 F A 
130  8 4 4 ≥32 ≤0.007 0.015 2 27 F A 
131  0.125 0.25 4 ≥32 ≤0.007 ≤0.007 2 27 F N 




133  0.5 4 4 ≥32 0.015 ≤0.007 1 24 M A 
134  0.125 4 4 ≥32 ≤0.007 ≤0.007 0.5 29 F A 
135  8 4 4 ≥32 0.06 0.015 1 31 M A 
136  0.5 4 4 ≥32 ≤0.007 ≤0.007 2 24 M A 
137  1 4 4 ≥32 0.03 0.015 1 25 M A 
138  8 ≤0.007 ≤0.007 ≥32 0.015 0.015 2 35 M A 
139  2 0.25 0.5 ≥32 ≤0.007 ≤0.007 0.5 44 M A 
140  0.25 4 4 ≥32 0.015 ≤0.007 0.5 20 M A 
141  8 1 2 ≥32 ≤0.007 ≤0.007 0.5 31 M A 
142  2 4 4 ≥32 0.125 0.06 1 27 M A 
143  0.5 4 4 ≥32 ≤0.007 ≤0.007 0.5 34 M A 
144  8 1 2 ≥32 0.03 0.015 0.5 35 M A 
145  0.5 1 2 ≥32 0.06 0.015 1 23 M A 
146  8 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 34 F A 
147  0.125 4 4 ≥32 ≤0.007 ≤0.007 2 36 M A 
148  4 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 32 F A 
149  2 ≤0.007 ≤0.007 ≥32 0.06 0.03 2 52 M N 
150  8 4 4 ≥32 0.06 0.03 2 22 M D 
151  4 1 2 ≥32 0.06 0.03 1 39 M A 
152  0.125 ≤0.007 ≤0.007 16 0.03 ≤0.007 1 26 M A 
153  4 ≤0.007 ≤0.007 ≥32 0.03 0.015 0.5 25 F A 
154  8 0.25 0.5 ≥32 0.015 0.015 0.5 31 M A 
155  2 1 2 ≥32 0.06 0.015 1 26 M A 
156  0.25 4 4 ≥32 0.03 ≤0.007 1 24 M A 
157  0.25 4 4 ≥32 0.015 ≤0.007 1 23 M A 
158  0.5 4 4 ≥32 0.015 ≤0.007 2 23 M A 
159  8 4 4 ≥32 0.03 ≤0.007 1 23 M A 




161  0.125 ≤0.007 ≤0.007 ≥32 0.015 ≤0.007 1 27 F A 
162  0.25 4 4 ≥32 0.015 ≤0.007 1 33 M A 
163  0.25 4 4 ≥32 0.015 ≤0.007 2 26 M A 
164  0.125 ≤0.007 ≤0.007 ≥32 0.015 ≤0.007 0.5 30 M A 
165  0.5 ≤0.007 ≤0.007 16 0.06 ≤0.007 1 30 M A 
166  8 1 2 ≥32 0.06 0.03 1 26 F A 
167  8 2 4 ≥32 0.015 ≤0.007 2 38 M A 
168  0.125 ≤0.007 ≤0.007 16 0.015 ≤0.007 0.5 30 M N 
169  4 4 4 ≥32 ≤0.007 ≤0.007 0.5 32 M A 
170  8 4 4 ≥32 0.125 0.06 2 28 M D 
171  4 1 2 ≥32 0.125 0.03 1 35 M A 
172  1 2 4 ≥32 ≤0.007 ≤0.007 2 26 M A 
173  4 0.015 0.03 ≥32 0.125 0.03 2 21 F N 
174  0.25 4 4 ≥32 0.015 ≤0.007 1 26 M A 
175  8 4 4 ≥32 0.125 0.015 2 24 M D 
176  4 1 2 ≥32 0.03 0.015 0.5 23 M A 
177  2 0.015 0.03 ≥32 0.06 ≤0.007 1 22 M A 
178  8 2 4 16 0.06 0.015 1 32 M D 
179  8 0.015 0.03 ≥32 0.015 ≤0.007 0.5 23 M A 
180  2 4 4 ≥32 0.25 0.03 1 25 M A 
181  8 0.5 1 ≥32 0.015 ≤0.007 1 33 M A 
182  0.5 2 4 ≥32 0.03 ≤0.007 2 32 M A 
183  4 4 4 ≥32 0.03 0.015 2 24 M A 
184  2 4 4 ≥32 ≤0.007 ≤0.007 4 18 F N 
185  8 ≤0.007 ≤0.007 ≥32 0.03 ≤0.007 0.25 26 F A 
186  0.25 0.015 0.03 ≥32 0.03 ≤0.007 2 22 F N 
187  0.5 1 2 ≥32 0.25 0.125 1 26 M A 




189  0.5 2 4 ≥32 0.03 ≤0.007 2 27 M A 
190  8 2 4 ≥32 ≤0.007 ≤0.007 0.25 32 M A 
191  0.25 2 4 ≥32 ≤0.007 ≤0.007 2 25 F A 
192  0.125 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 23 F A 
193  8 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 26 M A 
194  0.5 4 4 ≥32 ≤0.007 ≤0.007 1 20 M A 
195  8 1 2 ≥32 0.06 0.015 2 44 M A 
196  4 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 26 M A 
197  2 0.5 1 ≥32 0.03 0.015 1 36 M A 
198  8 0.5 2 ≥32 0.03 0.015 1 19 F A 
199  4 1 2 ≥32 0.03 0.03 1 27 F A 
200  8 0.5 2 ≥32 0.06 0.03 1 20 M A 
201  0.25 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 31 M A 
202  8 0.5 1 ≥32 0.03 ≤0.007 0.5 25 M A 
203  0.25 1 2 ≥32 0.03 ≤0.007 1 24 M A 
204  8 2 4 ≥32 0.015 ≤0.007 2 29 F A 
205  8 2 4 ≥32 0.03 ≤0.007 1 28 F A 
206  0.25 0.125 0.5 ≥32 ≤0.007 ≤0.007 1 28 M A 
207  8 1 2 ≥32 0.06 0.03 1 25 M A 
208  0.25 0.125 0.25 ≥32 ≤0.007 ≤0.007 4 31 M A 
209  8 0.03 0.06 ≥32 ≤0.007 ≤0.007 0.5 34 M A 
210  2 1 1 ≥32 0.015 ≤0.007 1 22 M A 
211  8 4 4 ≥32 0.06 0.015 2 27 F A 
212  0.25 4 2 ≥32 0.015 ≤0.007 2 23 F A 
213  8 2 2 ≥32 0.03 ≤0.007 0.5 19 M D 
214  4 0.03 0.06 ≥32 ≤0.007 ≤0.007 1 26 M A 
215  0.125 0.25 0.5 ≥32 ≤0.007 ≤0.007 0.25 28 M A 




217  8 ≤0.007 ≤0.007 ≥32 0.015 ≤0.007 0.5 25 M A 
218  4 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 29 F A 
219  2 0.5 1 ≥32 0.03 ≤0.007 1 25 F A 
220  0.25 ≤0.007 0.015 ≥32 ≤0.007 ≤0.007 2 31 M N 
221  0.5 2 4 ≥32 0.015 ≤0.007 1 38 M A 
222  0.125 4 8 ≥32 ≤0.007 ≤0.007 0.25 30 F A 
223  8 ≤0.007 0.03 ≥32 ≤0.007 ≤0.007 2 20 M D 
224  2 4 4 ≥32 0.03 ≤0.007 0.5 22 F A 
225  0.25 4 8 ≥32 ≤0.007 ≤0.007 2 24 F A 
226  8 ≤0.007 ≤0.007 ≥32 0.015 ≤0.007 1 22 M A 
227  4 4 4 ≥32 0.015 ≤0.007 0.25 29 M A 
228  8 4 4 ≥32 0.015 0.015 0.5 22 F A 
229  4 4 8 ≥32 0.015 ≤0.007 1 29 F A 
230  2 4 4 ≥32 0.015 ≤0.007 0.5 19 F A 
231  8 4 4 ≥32 0.015 ≤0.007 0.5 32 M A 
232  1 1 2 ≥32 0.03 0.015 0.5 34 M A 
233  8 4 4 ≥32 0.03 ≤0.007 0.5 32 M A 
234  8 4 4 ≥32 0.03 ≤0.007 2 24 F A 
235  2 2 4 ≥32 0.03 ≤0.007 1 27 M A 
236  2 2 2 ≥32 0.03 ≤0.007 0.25 29 M A 
237  8 0.015 0.015 ≥32 0.015 0.015 2 29 M N 
238  8 1 1 ≥32 0.03 0.015 0.5 23 M A 
239  0.5 4 4 ≥32 0.03 ≤0.007 0.5 29 M A 
240  0.25 2 4 ≥32 0.015 ≤0.007 0.5 18 F A 
241  0.25 0.015 0.03 ≥32 0.015 ≤0.007 1 28 M A 
242  0.25 4 8 ≥32 0.03 ≤0.007 1 27 M A 
243  8 4 4 ≥32 0.06 0.015 0.5 29 M A 




245  2 4 4 ≥32 0.03 ≤0.007 0.5 19 M D 
246  2 4 4 ≥32 0.06 0.015 2 25 M D 
247  0.125 2 2 ≥32 0.015 ≤0.007 2 24 M A 
248  0.25 4 8 16 0.015 ≤0.007 2 26 F A 
249  8 4 4 ≥32 0.015 ≤0.007 1 31 M A 
250  2 0.015 0.015 ≥32 ≤0.007 ≤0.007 0.5 20 F A 
251  4 1 2 ≥32 0.125 0.06 1 35 M A 
252  4 0.015 0.015 ≥32 0.03 ≤0.007 0.5 32 F A 
253  0.25 4 4 ≥32 0.125 0.03 1 32 M A 
254  8 2 4 ≥32 0.015 ≤0.007 1 29 M A 
255  0.125 0.015 0.015 16 0.015 ≤0.007 1 26 M A 
256  0.25 ≤0.007 ≤0.007 ≥32 0.015 ≤0.007 2 26 M A 
257  0.5 4 4 ≥32 0.03 ≤0.007 1 25 M A 
258  4 1 2 ≥32 0.03 0.015 1 24 M A 
259  8 4 8 ≥32 ≤0.007 ≤0.007 1 26 M A 
260  4 0.03 0.06 ≥32 ≤0.007 ≤0.007 1 39 M A 
261  0.25 4 8 ≥32 0.03 ≤0.007 1 23 M A 
262  0.125 4 4 ≥32 ≤0.007 ≤0.007 0.5 34 F A 
263  8 1 2 ≥32 0.03 0.015 1 21 M A 
264  4 1 2 ≥32 0.015 ≤0.007 0.5 37 M A 
265  4 1 2 ≥32 0.03 0.03 2 31 M A 
266  4 1 2 ≥32 0.03 0.015 1 26 F A 
267  0.25 0.015 0.015 ≥32 0.015 ≤0.007 1 25 M N 
268  0.5 4 8 ≥32 ≤0.007 ≤0.007 1 25 F A 
269  0.25 2 4 ≥32 0.015 ≤0.007 2 54 M A 
270  4 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 0.5 32 F A 
271  0.5 2 4 ≥32 0.06 0.015 1 24 M A 




273  4 1 2 ≥32 0.06 0.03 2 31 M A 
274  8 4 4 ≥32 0.03 0.015 1 25 M A 
275  8 ≤0.007 ≤0.007 ≥32 ≤0.007 0.015 1 23 M A 
276  4 4 4 ≥32 0.06 0.03 2 19 M D 
277  4 1 2 ≥32 0.03 ≤0.007 1 21 F A 
278  0.25 0.015 0.015 ≥32 0.015 ≤0.007 2 27 M A 
279  0.25 4 4 ≥32 0.03 0.015 1 22 M A 
280  4 1 2 ≥32 0.03 ≤0.007 1 42 M A 
281  4 ≤0.007 ≤0.007 ≥32 ≤0.007 ≤0.007 1 27 M A 
282  2 8 4 ≥32 0.03 ≤0.007 1 37 M A 
283  8 ≤0.007 0.015 ≥32 0.015 ≤0.007 1 28 F A 
284  0.25 4 8 ≥32 0.015 ≤0.007 2 20 M A 
285  0.25 ≤0.007 0.015 16 0.03 0.015 2 24 M N 
286  0.5 2 4 ≥32 0.03 0.015 0.5 23 M A 
287  4 ≤0.007 0.015 ≥32 ≤0.007 ≤0.007 0.5 22 M A 
288  4 4 4 ≥32 0.03 0.03 2 30 M D 
289  8 2 4 ≥32 0.015 ≤0.007 1 23 M A 
290  4 4 4 ≥32 0.03 ≤0.007 1 20 M A 
291  8 4 4 ≥32 ≤0.007 ≤0.007 1 24 F A 
292  2 4 4 ≥32 0.06 ≤0.007 1 21 M A 
293  0.25 4 8 ≥32 0.015 ≤0.007 2 29 M A 
294  8 4 4 ≥32 ≤0.007 ≤0.007 2 27 F A 
295  0.125 0.015 0.015 ≥32 0.015 ≤0.007 1 25 M A 
296  0.5 0.015 0.015 ≥32 0.015 ≤0.007 0.25 23 F A 
297  2 4 4 ≥32 0.06 0.03 1 20 F D 
298  2 8 8 ≥32 0.06 0.015 2 18 F A 
299  8 4 4 ≥32 0.06 0.015 2 19 M A 




301  4 4 4 ≥32 0.06 0.015 1 21 M D 
302  2 4 4 ≥32 ≤0.007 ≤0.007 1 26 M A 
303  4 4 8 ≥32 ≤0.007 ≤0.007 2 24 F A 
304  4 2 4 ≥32 0.03 0.015 1 23 M A 
305  0.125 0.015 0.015 ≥32 0.015 ≤0.007 0.5 22 F N 
306  8 4 4 ≥32 0.06 0.03 1 24 M D 
307  2 0.015 0.015 ≥32 0.015 ≤0.007 0.5 34 M A 
308  2 4 4 ≥32 0.015 ≤0.007 1 22 M A 
309  4 4 4 ≥32 0.06 0.015 0.5 27 M D 
310  4 1 2 ≥32 0.03 0.015 0.5 26 M A 
311  8 2 2 ≥32 0.03 0.015 1 18 F A 
312  0.5 4 4 ≥32 ≤0.007 ≤0.007 2 22 F A 
313  0.25 0.015 0.015 ≥32 0.015 ≤0.007 2 25 F A  
314  2 1 2 ≥32 0.06 0.015 1 26 M A 
315  0.125 1 2 ≥32 0.03 ≤0.007 0.5 21 F A 
316  4 8 8 ≥32 0.015 ≤0.007 1 25 M A 
317  0.5 1 4 ≥32 0.03 ≤0.007 1 23 M A 
318  0.125 4 4 ≥32 ≤0.007 ≤0.007 0.25 25 M A 
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